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FOREWORD 
Dr. Thomas Starzl and his colleagues have since their Colorado days 
spearheaded the recognition of the occurrence of posttransplant 
lymphoproliferative disorders and in a series of publications have 
contributed to their understanding and treatment. In this issue of 
Current Problems in Surgery, Drs. Nalesnik, Makowka, and Starzl 
have produced a superb and comprehensive monograph on this 
subject. The article is a tour de force of combined basic and clinical 
sciences, together with a concrete exposition of the various clinical 
factors involved from etiology, recognition, and treatment to ultimate 
outcome. As frightening as these disorders are, the heavy price they 
exact still turns out to be a tolerable price for the benefits of organ 
transplantation in the population at risk, particularly in view of the 
fact, as amply shown in these pages, that with appropriate therapy 
the tumors may be cured or made to regress, often without sacrifice 
of the transplanted organ. 
In what must be considered a complicated subject, much of it at 
the very forefront of our expanding knowledge in transplantation bi-
ology, the authors have created a lucid and readily comprehensible 
masterpiece. The clinical features of the disease are highlighted by 
case reports, each accompanied by detailed comments and appro-
priate illustrations. 
While it is possible to operate an automobile without knowing 
anything about the principles of its construction, it is less satisfac-
tory to deal with biologic problems without understanding their 
mechanisms and the manner in which these mechanisms are stud-
ied. The major portion of the monograph may be read by an inter-
ested physician. For those who wish to have an understanding of 
the basic biologic mechanisms and the scientific techniques in-
volved, the authors have provided an appendix, a remarkably lucid 
exposition of the field. One suspects that this appendix in itself is 
destined to be a classic. It well repays reading and studying. 
Mark M. Ravitch, M.D. 
Editor-in-Chief 
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THE DIAGNOSIS AND TREATMENT OF 
PO STTRANS PLANT 
LYMPHOPROLIFERATIVE DISORDERS 
INTRODUCTION 
PRELIMINARY COMMENTS 
Posttransplant lymphoproliferative disorders (PfLDs) represent a 
dramatic and potentially life-threatening range of conditions which 
occur in approximately 2% of organ allograft recipients.t65 A number 
of factors must intersect to cause this syndrome, and the immune 
system plays a key role at each step along the way. The physician 
caring for the patient with PfLD is witness to the end result of a 
number of immune system disturbances, namely, (1) a state of gen-
eral immunosuppression which has been induced to permit smvival 
of a foreign graft, but which also has caused concurrent interference 
with the major defense system against viral infection; (2) infection of 
the lymphoid system itself with the Epstein-Barr virus (EBV) in most 
cases; (3) proliferation of lymphoid cells, induced by the virus; (4) 
severe curtailment of downstream host immune control mecha-
nisms against excessive lymphoproliferation; (5) the emergence of 
lymphocyte clones with distinct smvival advantage, caused by sto-
chastic events occurring during cell proliferation and leading to the 
formation of progressively more "malignant" clones. 
This pathophysiologic gridlock is further tightened by two thera-
peutic considerations: (1) intensive chemotherapy in a previously 
immunosuppressed patient may cause the rapid onset of dissemi-
nated infection; and (2) discontinuing immunosuppression, either to 
reestablish host immune control mechanisms or as a prelude to 
chemotherapy, may lead to graft rejection. 
It is obvious that manipulation of the immune system for pur-
poses of organ transplantation must also take into account the mul-
tiple roles of this system in defense against both viral infection and 
tumor development. This monograph will review these various func-
tions of the immune system and will point out how maladjustments 
of these interrelated functions can lead to posttransplant lympho-
proliferative disorders. In summarizing our experience at the Univer-
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sity of Pittsburgh, we will show the range of proliferations that con-
stitutes the syndrome of PI'LD and we will stress the efficacy of a 
reduction in immunosuppression as a primary therapeutic interven-
tion. We will also demonstrate the fatal outcome when diagnosis 
and therapy are delayed for whatever reason. 
Throughout the course of this review references are made to re-
combinant DNA techniques, oncogenes, methods of clonal determi-
nation, and the cellular and humoral aspects of the immune re-
sponse. A more detailed contextual discussion of these subjects is 
deferred to the Appendix. This will serve more effectively to direct 
the reader's attention to those basic concepts that lead directly to 
an appreciation of the clinical and therapeutic aspects of PTLD. 
GENERAL SUMMARY OF POSITRANSPLANT 
LYMPHOPROLIFERATNE DISORDER 
Posttransplant lymphoproliferative disorder is used in this mono-
graph as a generic term to describe proliferations of B-lymphocytes 
that occur in immunosuppressed transplant recipients.90,244 Most if 
not all cases are associated with infection by EBV,121, 218 which is the 
causative agent of infectious mononucleosis and a cofactor in non-
Hodgkin's lymphoma of the Burkitt subtype.31,32,81 Most transplant 
patients who are infected with this virus do not develop PTLD154 
Therefore, other cofactors must also be operative. 
Infectious mononucleosis in normal individuals causes a prolifer-
ation of B-lymphocytes.210 This proliferation is controlled by multiple 
host defense mechanisms, especially by the proliferation and activity 
of cytotoxic T-lymphocytes.210 In organ transplant recipients, this T-
lymphocyte defense system is suppressed to varying degrees by an-
tirejection agents. Therefore the ability to control the B-Iymphocyte 
proliferation may be seriously impaired. 
There are several clinical categories of presentation for PTLD.107-
111,244 The patient may have an infectious mononucleosis-like syn-
drome, usually of exaggerated severity with respiratory compromise 
or cervical mass. In other cases, isolated organ dysfunction may oc-
cur due to infiltrative or tumorous PTLD. This presentation may lo-
calize to the allograft organ. The gastrointestinal tract and central 
nervous system are also common sites of involvement. There is some 
variability of localization depending upon the particular immuno-
suppressive regimen used.18s Finally, the patient may present with 
widely disseminated disease, often in association with serious infec-
tion. 
Diagnosis is made by biopsy. The pathologic appearance of PTLD 
reflects its lymphoid origin.90 Early lesions appear reactive and show 
maturation of B-Iymphocytes. The intense B-Iymphocyte prolifera-
tion and subsequent maturation produce a mixed Ipolymorphic) ap-
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pearance that may be mistaken for non-Hodgkin's lymphoma. If the 
proliferation is allowed to continue, the likelihood of malignant 
transformation increases. Histology is a helpful but not absolute in-
dicator of this change. At the time of diagnosis, serologic evidence of 
EBV infection should be sought and tumor tissue should be kruyo-
typed and evaluated for clonal composition and presence of EBV 
genome. 
Therapy is directed toward surgical relief of local complications 
and toward regression of tumor.244 Regression is effected by a partial 
or sometimes complete reduction of immunosuppression. In many 
cases an equilibrium can be achieved that will allow enough im-
mune reconstitution to involute the proliferation, but not enough to 
reject the allograft. Control of the lymphoproliferation is of overrid-
ing concern in most cases. 
The large majority of tumors fully respond to these measures. 
Early lesions may also respond to acyclovir therapy.lo9 Traditional 
antilymphoma therapy should be reseIVed for the rare case not re-
sponsive to these measures. Such nonresponsive tumors often result 
from a failure to recognize and treat the tumor during its earlier 
stages of development. 
The significance of PTLD, beyond its immediate import to the af-
flicted patient, lies in its central position via-a.-vis the processes of 
viral oncogenesis, immunosuIVeillance against neoplasia, and tumor 
progression in the human system. 
CANCER AND THE IMMUNE SYSTEM: HISTORICAL 
CONSIDERATIONS 
Interactions between the neoplastic process and the immune sys-
tem have long been a subject of investigation and controversy. The 
first expression of a relationship between these two subjects is at-
tributed by Kleinl45 to Paul Ehrlich: 
Ich bin uberzeugt, dass aberrierende Keime bei dem kolossal komplizier-
ten Verlauf der fOtalen und post-fotalen Entwicklung ausserordentlich hiiu-
fig vorkommen, dass sie aber glucklicherweise bei der uberwiegenden 
Mehrzahl der Menschen vollkommen latent bleiben, dank der Schutzvorri-
chtungen des Organismus. Wurden diese nucht bestehen, so konnte man 
vermuten, dass das Karzinom in einer geradezu ungeheuerlichen Frequenz 
auftreten wurde. 
(I am convinced that aberrant germs appear very often during the fetal 
and neonatal development periods, which are extremely complicated. For-
tunately, these germs remain inactive in the majority of people because of 
the immune system. If this self-protection did not exist, we could expect 
that carcinomas would appear with overwhelming frequency.)" 
·From Klein G: Tumor immunology. Transplant Proc 1973; 5:31-41. Used by 
permiSSion. 
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Attributing a "policeman's" role to the immune system in the pro-
tection of the host against cancer development was a theme that 
would be iterated a half century later by Lewis Thomas.255a Discuss-
ing the implications of the newly relevant organ transplant rejection 
phenomenon, Thomas suggested: 
"Is it possible ... that the underlying mechanism brought into play was 
not originally intended to cope with either bacteria or grafts? . . . Perhaps, 
in short, the phenomenon of homograft rejection will tum out to represent 
a primary mechanism for natural defense against neoplasia. 
. . . I have one other possibility to suggest. This concerns the fetal pla-
centa and, perhaps, the phenomenon of parturition, which may also involve 
mechanisms symbolized by homograft rejection." 
While the ability of the placenta to withstand immunologic rejec-
tion may indeed have implications for organ transplantation at some 
point in the future, it was the suggestion of a role of the immune 
system in cancer control that dominated investigative thought. 
The concept of "immunologic sUIveillance" against tumors was 
most strongly promulgated in the writings of Burnet,32-35 who also 
cited Ehrlich as the source of much of his thinking. Burnet, who 
expounded the theory of clonal selection first proposed by J erne in 
1955, had previously and correctly championed this theory as the 
basis for the diversity of antibody production. Applying the concept 
of clonal selection to the subject of neoplasia, he suggested a com-
petitive struggle for survival not only between the host and tumor 
but also among the tumor cells themselves. 
In his model Burnet hypothesized that, during the course of evo-
lutionary development, it became necessary for organisms to distin-
guish self from non-self. This ability conferred a survival advantage 
on those species able to recognize and thus to defend against para-
sitic life forms. However, the genetic diversity needed to generate a 
mechanism for the recognition of individuation introduced an ele-
ment of looseness into previously restricted genetic control mecha-
nisms. The benefit of this laxity was the development of the immune 
system. The price was the propensity to develop cancer, which arose 
from somatic mutations. The two processes developed around the 
same time in evolutionary terms. (We will later demonstrate how this 
"looseness" can be exploited to diagnose PrLDs and how it may also 
contribute to their pathogenesis in some cases.) 
More specifically, Burnet used the term "immunologic surveil-
lance" to refer to "the concept that a major function of the immu-
nologic mechanisms in mammals is to recognize and eliminate for-
eign patterns arising in body (sic) by somatic mutation or some 
eqUivalent process. From the point of view of survival, this is impor-
tant primarily as providing a means by which the appearance of ma-
lignant disease may be effectively cut short."36a Further, he attributed 
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this role to the thymus dependent system, in light of what was 
known at the time regarding the immune system and its role in or-
gan rejection phenomena. 
The immune surveillance theory logically predicted that individu-
als with immunodeficiency would have an increased incidence of 
cancer. Studies of congenitally immunodeficient patients revealed 
just such an increased incidence of malignancy, up to 10% in some 
groups.% 95, 98, 136 In addition, an increased incidence of neoplasia 
was also found in immunosuppressed transplant recipients.186,245,246 
However, it soon became apparent that this did not reflect an 
across-the-board increase in all forms of cancer.86, 125, 136 In particular, 
the more common forms of neoplasia were underrepresented, and 
an inordinately high frequency of "lymphomas" was seen.18S This 
epidemiologic finding was one of several phenomena unanticipated 
by the immune surveillance hypothesis. The narrow range of tumors 
found with some regularity in immunodeficient patients led to seri-
ous doubts regarding the general application of immune surveil-
lance to all human tumors.155 
The statistics regarding the increased incidence of neoplasia were 
also questioned on the basis that the population of patients at risk 
was unknown. This particular criticism has been addressed with 
time. FOI' example, one center for the reporting of these lesions was 
the Immunodeficiency Clinic at Memorial Sloan-Kettering Hospital, 
founded in 1973 by Good, a student and colleague of Thomas. (The 
Center moved to Mount Sinai Medical Center in 1976.) As of 1987 
this center recorded 114 cases of malignancy in patients with com-
mon variable immunodeficiency. The most recent report from this 
center62 showed cancer in 11 of 98 patients (11%) with common var-
iable immunodeficiency prospectively followed for periods of 1-13 
years. However, eight of the 11 cases were lymphoid in origin. Other 
similar studies have also found increases in gastric carcinomas in 
these patients.lIB,138 The general estimation of a 10% incidence of 
cancer in congenitally immunodeficient patients, such as those with 
Wiskott Aldrich syndrome, or ataxia telangiectasia, has also been up-
held.194 
A separate line of criticism against immunosurveillance concerned 
the development of tumors in nude mice. These congenitally 
athymic mice are characterized by a lack of T-Iymphocyte activity, 
Accordingly, they should be expected to have an increased inci-
dence of neoplasia. However, this was not the case.174, 223 Additional 
evidence against the T-cell immune system as the executor of im-
mune surveillance was the fact that this system in general required 
a certain time period to respond to an antigenic challenge and pos-
sibly did not recognize extremely low levels of antigens. Therefore, 
the role of the thymic dependent T-Iymphocyte as the specific effec-
tor arm of immune surveillance was seriously questioned. In re-
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sponse to this, attempts were made to transfer the effector role over 
to other cell types, specifically macrophages or natural killer cells.2so 
A third logical inconsistency developed when it was discovered 
that, although some antigenic tumors were able to "sneak through" 
the immune system in experimental models,22,67 many spontaneous 
or induced tumors lacked strong antigenicity.14s,148 It could be ar-
gued that this lack of antigenicity allowed them to subvert the sur-
veillance mechanisms.2z:1 However, one was also led to question the 
utility of an immune monitoring system based on detection of anti-
genic differences when the targets often did not express these anti-
gens?96 Indeed, evidence was presented that, under certain condi-
tions, the immune system might actually stimulate tumor growth.19S 
Though one can disprove the original premises of an argument, it 
does not necessarily follow that the conclusion is false. The undis-
puted fact that a select group of neoplasms emerge in the setting of 
an immunocompromised state may indicate that the normal host 
has developed a powerlul defense system against a limited number 
of malignancies.20o This point of view was expressed by mUltiple in-
vestigators, in particular, the Kleins,t4o-148 who stressed the role of 
the immune response in protecting against viral oncogenesis. Even 
critics of the immune sUIveillance hypothesis as originally proposed 
have acknowledged the existence of an analogous system in a select 
population of cases.lS5 251 Conversely, strong proponents of immu-
nosUIveillance have agreed that the original concept of a T-cell de-
fense against all forms of cancer is no longer tenable.142,148 
It should be noted that reviews of immunodeficient or immuno-
suppressed populations have shown low-grade increases in tumors 
other than lymphomas.62, 138, 185, 241 It is likely that the full range of 
immunodeficiency-associated cancers is not yet defined. In this re-
gard transplantation offers a unique vista from which to understand 
and devise treatments for such disorders. The various immunosup-
pressive regimens necessary to sustain graft sUIvival alter the im-
mune system in divergent, yet reproducible, ways. By analyzing the 
behaviors of the consequent tumors and their response to a reversal 
of immunosuppression, we may learn which host factors are crucial 
for tumor control. This may ultimately be of use for the prevention 
of PTLDs, and for the treatment of tumors arising in constitutionally 
immunosuppressed patients. 
THE EPSTEIN-BARR VIRUS AND NEOPLASIA 
EPSTEIN-BARR VIRUS BIOLOGY AND INFECTION 
Epstein-Barr virus is a ubiquitous virus that infects most of the 
world's population. From an evolutionary perspective, a symbiosis 
with man has developed such that infection with the virus at an 
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early age is associated with no clinical manifestations. With the ad-
vent of industrial society and improved hygiene, infection is often 
delayed until the second or third decade. In these cases infection 
usually results in infectious mononucleosis. Once infected, a stable, 
lifelong virus carrier state develops regardless of the age at exposure. 
Powerful host control mechanisms that maintain this host-virus bal-
ance have only recently begun to be understood. A review of normal 
EBV infection and its control by the host is helpful in understanding 
the derangements that can lead to PfLD. 
Epstein-Barr virus is a double-stranded DNA virus of the Herpes-
virus family.173a The complete nucleotide sequence of the virus was 
deciphered in 1984.10 It was first isolated by Epstein and his co-
workers in 1964 from specimens sent to his laboratory in Bristol, 
England, by Sir Dennis Burkitt, who was investigating a childhood 
tumor in Africa later to be known as Burkitt's lymphoma. Thus, at 
its very outset EBV was strongly implicated as a human tumor virus. 
In 1967, a laboratmy technician contracted infectious mononucleo-
sis while working with the recently discovered virus. In this manner 
the etiologic agent of mononucleosis was discovered.114 The virus 
has also been associated with nasopharyngeal carcinoma, lympho-
proliferative disease in immunosuppressed humans and in some 
nonimmunosuppressed species of subhuman primates,233 some 
cases of CNS lymphomas,4 some salivary gland tumors,51 and a more 
recently observed disorder termed chronic infectious mononucleo-
sis. I3l,211,248 Expanded numbers of EBV-containing cells have been 
described in patients with chronic lymphocytic leukemias and rheu-
matoid arthritis.258 The virus is not thought to be causative in these 
two disorders, and the significance of these associations is not 
known. Garden variety non-Hodgkin's B-celllymphomas do not nor-
mallv exhibit evidence of EBV involvement.4 
The virus replicates in epithelial cells of the oropharynx236 and in 
the parotid gland.267 From these sources, the circulating B-Iympho-
cyte pool is also infected.268 The shedding of infectious virus in the 
saliva also accounts for the mode of transmission. 
The virus enters B-Iymphocytes via the complement receptor 
C3d13o,179 and penetrates the cell within 12 hours in vitro.173a There 
are four stages to the life cycle: latent, followed by early, middle, and 
late replicative. All infected cells express Epstein-Barr nuclear anti-
gens (EBNAs) of which several types are known. Concurrently, lym-
phocyte-determined membrane antigen (LYDMA) is produced. Early 
antigens (EAs) are produced during the early replicative phase and 
are necessary for DNA synthesis, which occurs during the middle 
replicative phase, or during the S-phase of the cell cycle.104 DNA rep-
lication in productively infected cells apparently utilizes viral DNA 
polymerase, which is sensitive to acyclovir.52 In latently infected cells 
acyclovir has no effect on virus replication, suggesting that that virus 
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utilizes a cellular DNA polymerase.52,237 Latency may be dependent 
on cellular as well as viral factors.s3 Additional membrane antigens 
(MA) and viral capsid antigens (VCA) are formed during the late rep-
licative period. The virus is often present in mUltiple copies. It may 
integrate into the host genome]7! or may exist as free episomes. 
In addition to viral replication, polyclonal proliferative activity is 
also induced within the B-Iymphocyte itseles,29 In vivo, approxi-
mately 5%-20% of circulating B-cells are positive for EBNA during 
the first week of IM.213 These cells resemble plasma cells213 and have 
been shown to produce immunoglobulins in vitro.214 By the second 
week of 1M, <2% of circulating B-cells are positive for EBNA, and the 
majority of these infected B-cells no longer show plasmacytic differ-
entiation.213 
The host response to infection is complex, interactive, and incom-
pletely understood. Early host response to infection includes NK cell 
activity and interferon production.133 Interferon production probably 
begins before the onset of clinical illnessz53 and decreases rapidly 
thereafter.z5 An enzyme induced by interferon, 2',5'-oligoadenylate 
synthetase, also decreases shortly thereafter. Levels of this enzyme 
have been correlated to levels of CD8 + cytotoxic/suppressor T -cells 
that occur early in the disease.25 NK cells have activity against pro-
ductively infected cells, but show less activity against latently in-
fected cells. In vitro, T-cell-derived factors (probably gamma inter-
feron) delay, but do not prevent, B-cell transformation by the virus.zlO 
The early T-Iymphocyte response, referred to above, is thought to 
provide cytotoxic activity in a non-HLA-restricted manner and ac-
counts for the atypical lymphocytosis of the disease. This activity is 
later surpassed by the emergence of a strong T -cytotoxic/suppressor 
(Tc/s) population7],]40,210 which appears around 2 weeks after infec-
tion?33 These latter cells are directed against LYDMA, are HLA-
restricted210 and are also thought to playa role in suppressing the 
maturation of B-cells into plasma cells. The exact contributions of 
cytotoxic versus suppressor activities are a matter of some debate at 
present. Some T-cell activity may also be stimulated by B-cell prolif-
eration per se. This T response may represent an exaggerated form 
of physiologic control mechanisms operative in dampening a normal 
immune response.140 The Tc/s cells, by their cytotoxic actions, liber-
ate EBNA from infected cells. Although EBNA production is seen 24-
48 hours after virus infection of B-cells in vitro, anti-EBNA antibodies 
are not detected until 30-50 days after the onset of illness. It is 
thought that this delay reflects the time necessary for the host to 
first destroy EBNA-cantaining cells, thus making this nuclear antigen 
accessible to the humoral immune system.210 In vivo, antibody re-
sponses are first seen against early antigens (anti-EA) and viral cap-
sid antigen (anti-VCA). The anti-VCA antibodies are initially IgM, later 
superseded by IgG. Antibodies are also produced against the mem-
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brane antigen complex. Defective antibody responses to EBV infec-
tion may be seen in immunocompromised patients.115 The serologic 
changes of infectious mononucleosis are more fully discussed in the 
classic review of Henle and Henle.116 
Although the infection and subsequent polyclonal B-Iymphocyte 
proliferation are eventually brought under control by the host im-
mune response, the infection persists indefinitely in a latent form. 
Recent evidence has suggested that a low-grade steady state equilib-
rium is established among virus replication in the oropharynx, B-cell 
infection, and B-cell destruction by immune effector mechanisms.268 
It is hypothesized that virus replication occurs in the oropharynx, 
and it is at this site that B-Iymphocytes are infected in low numbers. 
As they recirculate, a stage is reached at which LYDMA and EBNA 
are expressed in the infected cells. At this point they are subject to 
immune destruction, mainly by the cytotoxic T-Iymphocytic com-
ponent of the immunosUIveillance system.210 It has been estimated 
that 0.01%-0.1% of circulating T-Iymphocytes in serologically posi-
tive individuals have anti-LYDMA activity. It is thus argued that this 
immunosUIveillance system alone should be capable of destroying 
isolated nests of latently infected cells unless they are replaced by 
newly infected cells. In addition, the obseIvation that anti-EBNA lev-
els are generally elevated at a constant level for life also suggests that 
a steady state has been reached whereby the destruction of small 
numbers of EBNA-positive infected B-Iymphocytes maintains a de-
tectable level of antibody production. 
The concepts presented here are derived in large part from the 
recent excellent review of EBV-host interaction by Rickinson.210 
EBV-ASSOCIATED NEOPlASIA 
Introduction 
The search for a viral origin of cancer was prompted by demon-
stration of similar systems in animals. However, despite the presence 
of some spontaneous systems of this sort operative in nature (e.g., 
Marek's disease in chickens) most work has been done with highly 
inbred animal species. Thus the applicability of these results to a 
highly outbred species such as man was difficult to establish. 
Today of course, retroviruses are known to be able to contribute 
to cancer in both direct and indirect fashions.2o,147,272 However, it 
was the discovery of the Epstein-Barr virus that marked the first 
solid link between a human virus and human cancer.81 Here we will 
consider the association of EBV in those cases of lymphoid neo-
plasms and disregard its role in other EBV-associated diseases such 
as nasopharyngeal carcinoma and undifferentiated carcinoma of the 
salivary glands. EBV-associated neoplasms in nontransplant popula-
tions will be discussed prior to a detailed consideration of PTLDs. 
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Burkitt's Lymphoma 
The discovery of Burkitt's lymphoma32 is a tribute to the perspi-
cacity and tenaciousness of Sir Denis Burkitt. At the time a surgeon 
at the Mulago Hospital in Uganda, he noted the prevalence of jaw 
tumors in children coming to his clinic. Frequently these tumors 
were seen in association with other concurrent neoplasms. Depend-
ing upon which specialist examined a given child, a different diag-
nosis was reached in each case. Burkitt realized that this fragmented 
approach could not decipher the true origin of these neoplasms, 
which appeared to constitute a distinct entity.31 When he discovered 
that the children were all from a geographically distinct area, he 
applied for, and received, two research grants totalling $75.00. With 
these funds he began his now famous epidemiologic studies that 
demonstrated the concordance in the distributions of Burkitt's lym-
phoma and hyperendemic or holoendemic malaria. In the course of 
these investigations, the Epstein-Barr virus was discovered in Burkitt 
lymphoma tumor samples. The events leading to this discovery are 
captured by Burkitt* with characteristic modesty: 
In 1961, I was lecturing to medical students at the Middlesex Hospital in 
London. The notice said something to the effect that an unknown guy from 
Africa would talk about an uninteresting tumor, if anyone happened to 
come along. For some reason Tony Epstein, who worked in a lab two blocks 
away, came and sat in the back. I had not spoken for more than 10 minutes 
when Tony recognized what I was saying as the missing piece of his jigsaw 
puzzle. He was looking for a human cancer that could be caused by viruses. 
He came up to me afterwards and asked if I could send him pieces of all 
our tumors. He would pay all the expenses, so I naturally accepted. We gave 
the tumors to the pilot in the BOAC plane, and he would bring them home 
to Tony, who would have them picked up at the airport. 
For three years, Tony and his colleagues looked for viruses but could not 
find any. Then they got the idea that if, perhaps, they cultured the biopsy 
first, it might be more helpful. So they did culture the biopsy. The first slide 
Tony looked at after culturing was full of viruses. He was so excited he was 
afraid the electron microscope might bum up his slide, so he switched it 
off and walked around the block to cool his head. When he came back and 
switched it on again the viruses were still there.31 
Epstein further tempered his enthusiasm in his initial 1964 report 
by stating that the virus probably represented a simple "passenger" 
in the tumor cells.81 However, the implications of this repor1 were 
apparent. 
In 1971, Manolov and Manolova discovered the characteristic re-
ciprocal translocation between the long arms of chromosome 8 and 
*From Burkitt DP: Discovering Burkitt's lymphoma: A special address to the 
Second International Symposium on the Epstein-Barr virus and associated diseases, 
in Levine PH, Ablashi DV, Nonoyama M, et al: EpsLein-Barr Virus and Human Dis-
ease. Clifton, NJ, Humana Press, 1987. Used by permission. 
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14 [t(8;14)(q24;q132)] in Burkitt lymphoma cells.166 This central dis-
covery was the first demonstration of what was later realized to be 
a mechanism for the activation of an oncogene, c-myc, in Burkitt's 
lymphoma.64 Variant translocations between chromosome 8 and ei-
ther chromosome 2 or 22, occurring in a minority of Burkitt lym-
phoma cases, would be found to have the same consequences.58-60 
In each case, the c-myc oncogene on chromosome 8 would be 
brought into apposition with the immunoglobulin heary (chromo-
some 14) or light (kappa 2, lambda 22) chain genes and be activated 
by mechanisms that are not yet clearKS~I 143, 156 These different trans-
locations apparently "freeze" the tumor cells at slightly different 
stages of maturation?9 
By 1979, a model of a multistep mechanism for the development 
of Burkitt's lymphoma was proposed by Klein.l44 According to this 
model, EBV infection of B-cells produced immortalized lymphocytes 
in vivo. Subsequently, chronic malaria resulted in B-cell stimulation 
secondary to the sustained presentation of antigen. Additionally, 
malaria induced a state of T-Iymphocyte suppression that resulted 
in a decrease of T-cell control over B-cell proliferation. Given this 
background, continued cell proliferation favored the occurrence of a 
genetic accident. In this case, any of the several translocations in-
volving c-myc could be associated with the entity known as Burkitt's 
lymphoma. Activation of additional oncogenes (e.g, B-Iym)72 was also 
considered likely in the further development of this disorder.143 The 
exact sequence of events and the role of the additional oncogenes 
are a matter of current debate. ls6 
Lymphocytes infected with EBV do not normally form tumors 
when inoculated into the immunodeficient nude mouse?80 Recently, 
it has been shown that insertion of the c-myc oncogene into lym-
phoblastoid cells infected with EBV resulted in tumorigenicity in this 
system, the degree of which was proportional to the amount of c-
myc expression.163 The authors speculate that the interaction of 
these two factors, EBV transformation and c-myc activation, may 
provide a necessary and sufficient condition for malignant transfor-
mation of these cells. If this is so, then this model represents an in 
vitro recapitulation of the in vivo events leading to Burkitt's lym-
phoma, acquired immune deficiency syndrome (AIDS)-lymphoma 
and probably fully malignant PTLD as well. The model does not ex-
clude the possibility of further or alternative forms of tumor progres-
sion. For example, evidence exists showing that EBV may activate 
other oncogenes indigenous to the host cell itself.206,254 
Reminiscent of some cases of PTLD, there are documented in-
stances of regression of Burkitt's lymphoma in humans.14s This phe-
nomenon is also rarely obseIVed in garden variety non-Hodgkin's 
lymphomas as well?51 
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Lymphoid Tumors in Congenital Immune Deficiency Syndromes 
In 1969, Purtilo performed an autopsy on an 8-year-old male who 
succumbed to infectious mononucleosis. Over the following 6 years 
he diligently pursued the underlying pathogenesis leading to the 
unfortunate and similar deaths of five other males in this family. 
This work led to the elucidation of the X-linked lymphoproliferative 
syndrome (XLP) in 19TRK19~g In this disorder, a specific defect exists in 
the host's ability to handle infection by the Epstein-Barr virus.204 
Following infection with EBV, approximately two thirds of males 
with XLP will develop life-threatening or fatal infectious mononu-
cleosis.zo1 In many of these cases, the cytotoxic T-cell response to 
EBV-infected B-cells is uncontrolled, and this immunologic war 
leads to destruction of innocent bystander organs, notably the liver 
and bone marrow. 
In approximately 35% of XLP cases malignant lymphoma may de-
velop, due to uncontrolled B-Iymphocyte proliferation following EBV 
infection.197 These tumors are very similar to PTLD occurring in al-
lograft recipients, and they appear to have a similar pathogenesis. 
Purtilo's hypothesis for the development of these lymphomas197 is 
based on an initial infection of B-lymphocytes by EBV. In the pres-
ence of immune hyporesponsiveness, an uncontrolled polyclonal tu-
mor may develop. With continued proliferation a cytogenetic error 
occurs and leads to the overgrowth of a malignant monoclonal lym-
phoma. Ths schema has recently been expanded to accommodate 
the multistep theory of carcinogenesis.2u1 Thus, two alterations of 
the B-cell are postulated as the intermediate steps leading from a 
polyclonal to a monoclonal tumor. These "hits" on the B-cell may 
correlate to the oligoclonal tumors described as part of this 
syndromezo1 and in transplant patients.45 The multiple hit concept 
also expands the hypothesis to accommodate the possibility that 
some proliferations, though of restricted clonality, may also be less 
than fully malignant. 
The term "opportunistic cancer"ZOl has been applied to these and 
other malignancies arising in immunosuppressed patients. This 
term emphasizes the link to an infectious, i.e., viral, etiology and the 
necessity for host immune defects in such disorders. Thus, it is a 
particularly apt descriptor. 
Using restriction-endonuclease probes,zz8 it has been possible to 
approximate the XLP locus on the sex (X) chromosome. This opens 
the possibility of diagnosis of the disease prior to EBV infection and 
the use of immune prophylaxis (e.g., gamma globulin) in such cases. 
Inherited immunodeficiencies in general represent a complex 
family of syndromes resulting from a large number of defects occur-
ring during immune system development. Immunologically, they 
can be simply divided into defects of the T- or B-cell systems, or 
both. 
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Lymphomagenesis in populations of congenitally immunodefi-
cient patients has been referred to above. The overall risk of devel-
oping a malignancy with a congenital immune deficiency is cur-
rently estimated at 4%, which represents a risk 10,000 times that of 
the normal population.127 
In addition to reports from the Immunodeficiency Clinic in New 
York62 (vide supra), the large Immunodeficiency Cancer Registry es-
tablished at the University of Minnesota in 197385,91,136 produced 
data that has recently been reviewed.127 We will not discuss this gen-
eral subject further except to note that children with Wiskott-Aldrich 
syndrome, a clinically distinctive but pathogenetically obscure de-
fect affecting both T- and B-cell systems, have the highest risk of 
developing malignancies, estimated at over 10% .62, 65, 194 This is par-
ticularly poignant in light of the fact that these unfortunate children 
do not usually survive beyond the first years of life. 
The most common tumors in all groups of congenitally immuno-
deficient patients are non-Hodgkin's lymphoma. Again, Purtilo197,200 
has emphasized the etiologic role of EBV in a number of these tu-
nl0rs, 
Similar to the case in transplant tumors,224 review of older reports 
of lymphomas in congenitally immunosuppressed patients has con-
tinuously modified and updated the pathologic interpretation.91 
Thus, we agree with Bird and Britton15 that noncritical propagation 
of the earlier (circa-1960-1970si literature on this subject may lead 
to fallacious conclusions. One case report of an EBV-associated lym-
phoproliferation in a congenitally immunodeficient patient serves to 
illustrate this. The case was originally considered to be polyclonal 
on the basis of immunophenotypic studies.2IZ Later studies of cells 
grown from this patient indicated a monoclonal component within 
the proliferation. The authors termed this an oligoclonal process, 
since other cells grown from the patient showed different clonal 
rearrangements.29 It is likely that many other cases would also be 
found to fit closely into the spectrum of lymphoproliferations de-
scribed for XLP patients201 and transplant recipients90 if the original 
material were recoverable. 
Some other cases have features suggestive, but not diagnostic, of 
an ineffective host response to EBV, sometimes with lymphoprolifer-
ative complications. Since T-Iymphocytes constitute the major pool 
of proliferating cells in the host's response to EBV infection, the pos-
sibility also exists that these cells may also give rise to a malignancy, 
Aronson et al.7 have reported a T-cell leukemia, diagnosed by clonal 
analysis of the T-cell receptor, that occurred in a young male 1 year 
after an atypical EBV infection. They postulate that the leukemic 
cells, which demonstrated some features of NK cells, may have rep-
resented a neoplastic clonal outgrowth of reactive cells that had 
originally been mobilized to fight the infection. Sullivan et al.252 doc-
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umented an exuberant T-cell proliferation that could have been eas-
ily mistaken for lymphoma in a lymph node of a patient with virus-
associated hemophagocytic syndrome. These authors considered 
this to be a manifestation of disordered host response to EBV infec-
tion in this case. 
Very rarely, acute EBV infection may be associated with the ap-
pearance of non-Hodgkin's lymphoma in patients with no obvious 
immune deficiencies.221 
Lymphoid Tumors in the Acquired Immune Deficiency Syndrome 
An increase in B-cell lymphomas in AIDS patients was first recog-
nized in 1982.209 By 1984, the clinicopathologic features of these tu-
mors were delineated in a multi-institutional report of non-Hodg-
kin's lymphomas seen in 90 homosexual men with AIDS.272 The 
tumors arose as growths of monoclonal B-lymphocytes and were fre-
quently, but not always, preceded by a lymphadenopathy syndrome 
(LAS) as part of the AIDS-related complex.157 
The AIDS lymphomas differed from regular non-Hodgkin's lym-
phomas in that they tended to occur in extranodallocations (espe-
cially the central neIVOUS system, bone marrow, and bowell and re-
sponded poorly to therapy in many cases.239,272 In this regard, we244 
noted the similarity between PTLD and AIDS lymphomas and sug-
gested that the insights provided by the reversibility of transplant 
lymphoproliferations "'rith reduction of immunosuppression might 
provide a stimulus to the use of immunoaugmentation techniques 
in AIDS-associated lymphomas. The fruits of this approach have 
not yet been realized, although the use of intert'eron to induce 
regression in AIDS-related Kaposi's sarcomas is becoming an ac-
cepted therapeutic modality. This response of Kaposi's sarcoma 
was also anticipated by the regressihility of similar tumors in 
transplant recipients subjected to a reduction of immunosuppres-
sion.165 
Subsequent studies of AIDS lymphomas have confirmed that their 
pathogenesis is strikingly similar to that of PTLDs. The polyclonal 
lymphadenopathy referred to above (LAS) was suggested as the soil 
from which monoclonal tumors could develop.271 Immunoglobulin 
gene rearrangement studies further revealed some of the LASs to be 
oligoclonal; that is, they were individual lesions composed of several 
proliferating B-cell clones. Rearrangement of the c-myc oncogene 
was obseIved in AIDS lymphomas but not in LAS biopsies.182 The 
HIV genome was not detected in lymphoma biopsies, suggesting that 
the virus did not play a direct part in the pathogenesis of this dis-
order. The current opinion is that these lymphomas may be a con-
sequence of EBV infection in many cases. This is supported by evi-
dence that the EB-viral load appears to increase in the saliva of AIDS 
patients as the severity of their underlying disease increases.z How-
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ever, the role of EBV in the initial polyclonal activation of B-cells 
remains a matter of debate.57 
The increase in AIDS-associated lymphoproliferations has led to 
closer study of the pattern of lymphoma development in general. 
One such study 3 found an increase in the percentages of high-grade 
lymphomas and extranodallymphomas in males with no known risk 
factors for AIDS. The study left open the question of whether or not 
this represented an absolute increase in these diseases, although the 
possibility was raised. This disturbing finding requires corroborative 
support. The role of EBV in these cases has not been investigated. 
An association of central nervous system lymphoma and EBV in pa-
tients with no evidence of immunodeficiency has also been re-
ported.12 
Other Neoplasms in Immune Deficient States 
Other forms of cancer, not clearly associated with EBV, have also 
been reported in many of the populations at risk for EBV-induced 
neoplasia. Indeed, the preponderance of lymphoid tumors serves to 
distract attention from the milder increases in other forms of can-
cer.18, 118, 124, 125, 136, 138, 189,241 It is not the purpose of this review to deal 
with cancers other than PTWs, but one point relevant to transplant-
associated neoplasia should be made in passing. 
In the case of organ transplant recipients, there are extraordinaI)' 
case reports of inadvertent transplantation of cancer cells that pro-
duced clinical disease in the recipient but regressed upon cessation 
of immunosuppression.95,266,274 One hepatic allograft recipient even 
rejected a donor hepatocellular carcinoma and its widespread pul-
monaI)' metastases.152 Unfortunately, this happy outcome is not the 
rule in most cases.231 However, it does demonstrate the power of the 
host immune response to reject foreign cells, even in some cases in 
which they are fully malignant. 
The interested reader is referred to the reviews of Penn/85,188-193 
Sheil,229-231 and Birkeland18 for discussions of the general incidences 
of different types of neoplasia in transplant recipients. When com-
paring frequency rates of neoplasia from different transplant series, 
however, it is necessary to ascertain whether or not skin cancers are 
included in the statistics. These tumors, related to geographic loca-
tions in general and sun exposure in particular, may significantly 
increase the number of tumors reported from a particular center.103 
TRANSPlANT-ASSOCIATED LYMPHOPROLIFERATIONS 
Introduction 
The existence of transplant-associated lymphoproliferations was 
discovered by Starzl in 1968.246 That same year, Penn192 instituted an 
informal registry of transplant tumors, located first in Denver and 
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later in Cincinnati. In 1969, the firse86 of a series of reports from this 
Center185, 187-193 defined the clinical dimensions of transplant-associ-
ated tumors. In 1970, the suggestion of reducing immunosuppres-
sion as a form of therapy for these tumors was first proposed.235,245 
By the time of the description of X-linked lymphoproliferative dis-
order, it was also known that allograft recipients had increased oro-
pharyngeal excretion of EBV.41. 247 In 1975, Matas e1 al.170 hypothe-
sized that the combination of Herpesvirus infection and iatrogenic 
immunosuppression was the cause of many of the tumors occurring 
in transplant recipients. In 1976, Matas et a1.169 tentatively suggested 
an association between EBV and PTLD. A case report of diffuse lym-
phoma in a renal transplant recipient occurring in association with 
infection by EBV, Herpes simplex, and parainfluenza appeared in 
1978.27 In that same year Iwatsuki, Geis, and their collaborators96,128 
also raised the question of an association of EBV and PTLD. Their 
report is memorable in that the lesions in their five patients all re-
solved without the use of antitumor therapy. 
In 1979, Marker et al.167 documented two cases of polyclonal PTLD 
arising in association with EBV infection, A similar association was 
soon reported by Nagington and Gray,177 who demonstrated EBV 
DNA within the tumor cells. In 1980, Crawford published a case re-
port of an EBV-positive PTLD occurring in a CyclospOlin A treated 
renal recipient.56 Purtilo, in 1980,203 suggested that immunosuppres-
sion of T-Iymphocytes directed against BBV-infected B cells might 
provide a mechanism for the tumorous expansion of B-Iymphocytes. 
These views were also adopted by Starzl et a1.243 
Ongoing collaborative efforts initiated by Purtilo and Klein and 
which centered on the University of Minnesota transplant popula-
tion provided definitive evidence for the role of EBV in PTLDs.1l0,218 
Similar results were later reported in studies of the transplant pop-
ulations at Stanford and at the University of Pittsburgh.50, 244 
By 1981, Frizzera, extending his work on lymphoid tumors in con-
genitally immunodeficient patients,91 recognized that EBV-associated 
transplant lymphomas actually represented a spectrum of disorders 
ranging from benign to malignant.9o Attention turned to the clinico-
pathologic categorization of patient populations,l()7-1l1,244 earlier di-
agnosis/.59,Z60 the specific role of EBV infection,l2l and the clonal 
composition of the proliferations.45, 50, 178,244 Treatment modalities by 
this time included acyclovir, reduction of immunosuppression, sur-
gical resection, chemotherapy, and radiotherapy in varying propor-
tions.107-111, 244 
Iatrogenic Immune Deficiency State of the Organ Transplant 
Recipient 
It would be pedantic to belabor the point that organ allograft re-
cipients sustain a state of general immunosuppression in order to 
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maintain a state of graft tolerance. Despite the fact that minor de-
grees of accommodation for coexistence occur on the parts of both 
the host and the allograft,135 it is the rare and unpredictable patient 
who develops a state of complete tolerance toward the transplant 
organ. 
It is worthwhile, however, to point out that immunosuppressive 
regimens differ qualitatively as well as quantitatively. In light of the 
observation that differences in phenotypic expression of PfLDs exist 
among patient populations suppressed with different drug regi-
mens, such differences may have clinical relevance. 
One integrated model of immunologic sites subject to pharmaco-
logic modulation is shown in Figure 1 ?35 It can be seen that separate 
but overlapping sites of action are proposed for the major immuno-
suppressive agents, cyclosporine (CsA), corticosteroids (S) and aza-
thioprine (Aza). 
Early reports of CsA use suggested that this agent was associated 
with a higher rate of lymphoma development than were other im-
munosuppressants.14,38,56 Further experience has not borne out 
these claims/5,37 255 even though the paralysis of T-cell function in-
duced by this drug has been exploited in vitro to promote sponta-
neous outgrowth of EBV-infected B-Iymphocytes?7,184 Cyclosporine 
inhibits mitogen- or alloantigen-induced lymphocyte proliferation, 
decreases release of IL-2 from T-cells, inhibits expansion of cytotoxic 
T-cell precursors, and inhibits the delayed hypersensitivity reaction. 
It also may selectively inhibit the T -dependent B-cell response and 
exhibit a relative sparing of T-suppressor cell activities in certain in-
stances.153,232 
The purine analog azathioprine becomes active during metabolic 
degradation. The resulting thioinosinic acid inhibits DNA, RNA, and. 
protein synthesis and acts particularly to inhibit the proliferative ac-
tivities of T- and B-cells. 
Corticosteroids bind to nuclear chromatin and can decrease the 
ability of lymphocytes to become activated, inhibit lymphocyte pro-
liferation, and inhibit memory cell generation. An intera.ction be-
tween steroids and CsA has been shown.149 In addition, steroids ex-
ert other, unrelated effects on immune responses as well as on the 
expression of MHC antigens on the donor organ.U3 
Some biologic reagents are also used as immunosuppressants. 
The newest addition to our biologic armamentarium is the mono-
clonal antibody OKT3,97 which binds to the CD3 antigen present on 
the surface of all T_cells.208 The CD3 (or T3) antigen normally acts to 
transduce the signal received by the cell when the T-cell receptor 
binds specifically to the antigen against which it is directed. The use 
of OKT3 antibody causes the CD3 molecule to disappear from the 
surface of the cell, resulting in cell paralysis. One major effect of this 
paralysis is the inhibition of T-cell cytotoxicity. This can be thera-
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FIG 1. 
Recognized sites of action of immunosuppressive agents in the allogeneic response. Aza, 
azathioprine; CsA, cyclosporin A; S, steroids; M, macrophage; Ts, T suppressor lym-
phocyte; Th, T helper lymphocyte; pcn, precytotoxic T lymphocyte; Tdth, T delayed-
type hypersensitivity cell; B, B lymphocyte; CTL, cytotoxic T lymphocyte; P, plasma cell, 
MIF, migration inhibition factor; etc. includes other Iymphokines associated with the de-
layed hypersensitivity response. (Adapted from Keown PA, Stiller CR: Control of rejection 
of transplanted organs, in Stollerman GH et al (eds): Advances in Internal Medicine, vol 
31. Chicago, Year Book Medical Publishers, Inc., 1986. Reproduced with permission.). 
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peutically useful for the reversal of acute rejection episodes. Our 
own experience with liver transplant recipients has substantiated 
this claim.92 One problem with this approach has been the devel-
opment by the host of antibodies directed against the OKT3 anti-
body.97 
Other biologic agents, such as Minnesota antilymphocyte globulin, 
are currently in use for the same purpose. The relative merits of 
OKT3 versus this agent have yet to be evaluated. All of these agents, 
even among themselves, show differential effects on circulating leu-
kocytes.102 
The list of drug effects could be extended further: cyclophospha-
mide shares many of the actions of azathioprine and the new and 
powerful experimental immunosuppressant FK506 (formerly 
FR900506)looa appears to function in a manner similar to, but more 
potent than, CsA. However, the significant obseIvation is that each 
immunosuppressive agent has its own mechanism of action. In ad-
dition to site differences, differences probably also exist in regard to 
the reversibility of effect following withdrawal of drug. In this regard, 
the immunosuppressive effects of CsA have been shown to be rap-
idly reversible following withdrawal of the drug. 
In attempts to compare PTLDs from different centers it is impor-
tant to realize that the particular drug regimen used in a given series 
may be a confounding variable. Our own series is heavily skewed 
toward patients who have received CsA-containing regimens.244 The 
use of this drug at our institution has resulted in increased sUIvival 
in general, due in large part to the better control of the acute rejec-
tion process within the first 6 months following transplant.99 
Risk Factors for the Development of Posttransplant 
Lymphoprolij'erative Disorder 
The occurrence of PTLD is dependent upon the presence of im-
munosuppression, Epstein-Barr virus infection, and other, poorly 
characterized factors. 
The type of immunosuppression is not as important as its pres-
ence and intensity. In the Australia/New Zealand renal transplant 
series, a 3% frequency of "lymphomas" was obseIVed.229,23o These 
patients were treated with azathioprine, steroids, and occasionally 
antilymphocyte globulin. No figures are yet available for the fre-
quency of PTLD with the use of OKT3, although the tumors have 
been documented to occur with the use of other monoclonal anti-
bodies directed against the CD3 antigen.l68 The extensive series of 
Pennl85-193 also demonstrates the occurrence of tUInors with all 
forms of antirejection immunosuppression. 
In a separate study of 5,550 allograft recipients treated with CsA, 
the overall frequency of PTLD was 0.7%.12 This was identical to the 
0.6% frequency within the subgroup of 4,000 renal recipients in-
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cluded in that series. However, when the renal subgroup was broken 
down by type of immunosuppression, differences were seen. Of 
3,900 renal recipients treated with CsA and low dose steroids, a 0.4% 
incidence was seen, whereas this rose to 8.0% in 100 renal recipients 
treated with CsA combined with ALG, ATG, cytostatic drugs, or tho-
racic duct drainage.12 On this basis Beveridge et al. stressed the need 
to avoid overimmunosuppression. They considered that maintaining 
blood trough levels of CsA between 200 and 1,000 nglml, or serum 
trough levels between 50 and 200 nglml, represented a desirable step 
in this direction. 
A case report of PTLD occurring in a renal transplant patient re-
ceiving CsA-prednisone, despite meticulous attention to maintaining 
acceptable trough levels of CsA, was reported from the Yale series 
the following year.13 On the basis of immunologic function tests in 
this patient, the authors suggested that the actual degree of func-
tional immunosuppression, rather than the blood level of drug, was 
the critical variable. Likewise, a separate case report documented 
two monoclonal paraproteins occurring in the presence of normal 
blood CsA levels?'" In this patient, who was receiving sulfinpyrazone, 
high doses of CsA were required to maintain normal serum levels of 
the drug. When the CsA dosage was lowered, the paraproteinemia 
abated. 
The constitutional role of the host immune system in tumor de-
velopment was analyzed in the Scandia Transplant material.19 Serial 
immune monitoring was performed in 10 patients who developed 
tumors following renal transplantation. Since only one of the tumors 
was lymphoid (Hodgkin's disease) and the immunosuppressive reg-
imens did not include CsA, the results cannot be directly applied to 
CsA-associated PTLDs. Nevertheless, this pioneer study showed sig-
nificantly decreased lymphocyte blastogenic responses in pretrans-
plant specimens from patients who later developed tumors, when 
compared to a control group of transplant recipients who did not 
develop tumors. In a closely related area of investigation, Cun-
ningham and Ascher61 reported an increased prevalence of viral 
infections in patients in whom pretransplant CD4: CD8 (helper: 
suppressor) ratios were ::;1.5 and who underwent conventional im-
munosuppression. The study stressed CMV infection and did not 
mention EBV. Similar results were not obtained when CsA-contain-
ing regimens were used. 
Guttmann and Meakins105 followed renal transplant patients with 
serial skin testing. They found that 14 of 18 patients with tumors 
developing after transplant had been documented to be anergic for 
a mean period of 2.8 years before tumor diagnosis. However, most 
tumors in this series were nonlymphoid, and not every patient with 
anergy went on to develop tumor. 
The role of EBV infection in the pathogenesis of PTLD was dis-
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cussed above. It should be emphasized that not every transplant pa-
tient with Epstein-Barr virus infection will go on to develop 
PTLD.30,117.121,154 Primary infection/21 infection in the face of high im-
munosuppression/a and high virus shedder status268, 269 appear to be 
likely candidates as variables whose presence augurs a significant 
risk of PTLD development. 
Since EBV is strongly implicated in the development of PTLD, the 
question of case clustering arises. We have not examined this statis-
tically in our own patient population, but have the impression that 
a weak temporal clustering may exist. More rigorously, however, Kin-
len and Hoover137 were unable to find evidence of space-time clus-
tering of PTLDs, despite a variety of statistical approaches. 
An association between EBV infection and mean cyclosporine 
blood levels as risk factors for the development of lymphoma was 
elucidated in the Stanford heart and heart/lung transplant series.30 
By EBV infection alone these investigators were unable to discrimi-
nate those patients who would go on to develop lymphoma from 
those who would not.Il7 However, when they coupled this with the 
mean esA levet they were able to construct a logistic regression pro-
file that to some degree separated out those patients at high risk for 
tumor. 
Chronic antigenic stimulation from the graft itself has been sug-
gested as a contributory factor in the development of PTLD. Small 
but measurable differences of tumor frequency are seen when recip-
ients of different organ types are compared. Renal recipients gener-
ally have the lowest, and hear1/lung recipients the highest, frequen-
cies. At our institution, the present frequency of PTLD is 1.0% in 
renal transplant patients, 1.8% in heart, 2.2% in liver, and 4.6% in 
heart!lung recipients. Several qualifying remarks must be made, 
however. First, the allografts associated with the higher frequencies 
of PTLDs also require higher immunosuppression. This alone places 
the patient at increased risk. Second, one study of heart and heart! 
lung recipients showed no difference in the number of rejection ep-
isodes between those patients who did and those who did not sub-
sequently develop lymphoma.3o Third, a learning CUIve is probably 
operative in transplant centers, and early frequency estimates of 
PTLDs may later decrease as the denominator increases. For in-
stance, the estimated 33% frequency in heart!lung recipients in our 
1984 report244 now stands at only 4.6% in 1987. Last, in one 
series229, 230 there appeared to be a greater tendency for patients with 
cadaver kidney transplants to develop tumors than for patients with 
living related kidney transplants to develop tumors. This argued that 
the additional antigenicity of the unrelated cadaver kidney may have 
played a pathogenetic role in this process. However, subsequent cor-
rection for age showed that the two patient groups were equally 
susceptible to cancer.231 In contrast to these findings, Birkeland has 
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reported a relationship between tumor development and degree of 
HIA mismatch.1s However, this Scandinavian series included a large 
number of nonlymphoid tumors. 
Regardless of these disclaimers, our own cases indicate that the 
lesions may initially present in the allograft organ, suggesting a 
cause and effect relationship. A tantalizing case report of a lympho-
proliferative disorder occurring in a bone marrow recipient docu-
mented the emergence of a neoplasm (of host origin) shortly after 
the appearance of a Coombs' positive hemolytic anemia.21 One ob-
vious inference is that the blood group mismatch stimulated host 
cells to produce antibody to the donor blood group antigen. From 
this stimulated B-cell pool a malignant clone emerged. Curiously, 
EBV could not be documented in this tumor despite the presence of 
reactivation infection. The absence of virus, which has occasionally 
been noted,t21 may represent a technical artifact or may point to 
other, unknown cofaclors in the development of PTLD. We68 have 
shown atypical lymphoid hyperplasia in nontransplanted rats who 
were fed oral CsA. This finding had not previously been re-
ported.84• 256. 257 These results are of interest since EBV does not have 
the ability to infect this species. 
In the case of bone marrow transplants, the risk for PTLD is sig-
nificantly increased when T-cell-depleted mismatched donor mar-
row is used.226 In one series/z6 a 24% frequency of PTLD was seen 
in this setting, compared to approximately 0% frequency when ei-
ther matched T-cell-depleted or matched non-T-cell-depleted mar-
row was used. 
The association of the original underlying disease that led to 
transplant and the propensity to develop PTLD has not been ana-
lyzed in our series. Some investigators have put forth statistical data 
to support such an association for the conditions of idiopathic 
cardiomyopathy 3,14 or polycystic kidneys124 and subsequent ten-
dency to develop PTLD. An association between chronic interstitial 
nephritis and tumor development (including non-PTLD types) has 
also been suggested. tB 
Pathology of Posttransplant Lymphoproliferative Disorder 
Macroscopic Appearance.-PTLDs demonstrate a number of ap-
pearances depending upon their growth patterns and locations. In 
esA-associated proliferations, most cases present with mass lesions, 
but a minority of PTLDs may assume an infiltrative form of growth. 
Tumorous lesions often contain a prominent necrotic component, a 
feature that may also be of use in the radiologic evaluation of these 
patients.263 
In our series, the head and neck and the gastrointestinal tract 
were the two areas most commonly involved by PTLDs. In the head 
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and neck, tonsils, lymph nodes, and salivary glands were the usual 
sites of tumor. The brain appears to be a target organ for the disease 
only in those allograft recipients who have received conventional 
(non-esA-containing) immunosuppression.185,193 In the Minnesota 
series, 14% of patients had disease confined to the eNS and a total 
of 45% had eNS disease, usually in association with widespread dis-
ease.108 
The tonsils, when involved, usually enlarge quite dramatically, of-
ten contain prominent necrosis and may cause acute respiratory 
embarrassment. Involved lymph nodes in the early stages maintain 
a smooth, circumscribed capsule and on cut sUIface display a uni-
form, gray-white to tan surface. The presence of necrosis is variable. 
With more advanced lesions, the capsule is breached, and the pro-
liferation invades into the surrounding soft tissues with attendant 
difficulties in any surgical resection. The appearance of the fully in-
volved node is indistinguishable from that of diffuse lymphoma. 
In the neck, tumors may also arise from the salivary glands. It is 
not certain whether these arise from salivary gland de novo or from 
lymph nodes in an intrasalivary location. 
As a general rule, the histologic changes in individual cases appear 
to be more fully expressed in the largest lymph nodes. This fact 
should be remembered when selecting a node for biopsy. Also, pa-
tients with predominant head and neck disease may have general-
ized adenopathy in addition to their major disease focus. The his-
tologic changes in lymph node biopsies taken from areas far 
removed from the main area of disease may be easily dismissed by 
the uninitiated as nonspecific reactive hyperplasia. This selVes as 
another caveat to the surgeon in selecting a biopsy site (see histo-
logic changes, below). 
Tumors involving the gut tend to be large, rapidly growing, and 
multiple (Fig 2). These lesions are seen more frequently in patients 
receiving eSA-containing regimens/85,244 although they are seen oc-
casionally with conventional immunosuppressive regimens?Z9,134 
Eleven of our first 44 patients had a primary gastrointestinal mani-
festation of PfLD. Involvement of areas rich in gut-associated lym-
phoid tissue is the usual case, although individual tumors have been 
seen in the stomach. The propensity of the tumors for local invasion 
and consequent tissue necrosis can quickly lead to perforation of 
the bowel wall; multiple perforations are not uncommon in un-
treated cases. Perforations may c;ause a free rupture into the perito-
neal cavity or may result in a Yarge mass composed of tumor and 
matted loops of bowel with signs and symptoms of complete or in-
complete intestinal obstruction. 
Viewed from the mucosal aspect, the fully developed intestinal 
PTLD presents an ulceronodular mass with a green-yellow pseudo-
membrane. In small lesions, the epicenter appears to arise from the 
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FIG 2. 
Region of ileocecal valve and ascending colon from a liver transplant recipient with PTLD. 
The specimen has been opened and is viewed from the mucosal aspect. Multiple ulcer· 
onodular tumors are evident. The patient is alive and well 4 years following tumor resection 
and reduction of immunosuppression. (From Makowka L, Nalesnik MA, Stieber A, et al 
Control of post-transplant Iymphoproliferative disorders and Kaposi 's sarcoma by modu-
lation of immunosuppression, in Good RA, Lindenlaub E (eds): Symposia Medica Hoechst. 
The Nature, Cellular, and Biochemical Basis and Management of Immunodeficiencies. 
Stuttgart-New York, FK Schattauer Verlag, 1987, pp 567-624. Reproduced with permis-
sion .) 
submucosa. In larger lesions the entire thickness of the bowel wall 
is obliterated by tumor. In one case in which clinical regression was 
documented (case 4, below), resection of regressing tumors showed 
shallow ulcers with white membranes forming on the surface of the 
ulcer. These membranes represented regenerating mucosa. 
In the lungs the tumors have a nodular shape and may be either 
single or multiple. This appearance is also appreciated on X-ray ex-
amination (see case 5, below). On cut surface the lesions are gray-
white, again raising the pathologic likelihood of a lymphoma. These 
lesions very often occur in association with nearby pneumonia. In 
our series, Pneumocystis carinii or CMV represented the organisms 
most often involved in this process. Pulmonary lesions may be the 
only site of disease or may be seen in association with disease in 
other organs. 
Lesions in solid organs may be tumorous or infiltrative. Tumors 
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are lobulated, gray-white and often contain obvious areas of necro-
sis. Infiltrative lesions may be inapparent on gross examination, or 
may impart a mottled appearance to the organ. The variegated ap-
pearance may be further accentuated by necrosis of the parenchy-
mal tissue. If the organ is an allograft, the possibility of rejection may 
be raised on gross examination. This is also a differential diagnostic 
consideration in the microscopic analysis. 
Microscopic Appearance.-It is well known that the lymphoid le-
sions associated with EBV infection may mimic malignant lym-
phoma of either Hodgkin'sl72,219 or non-Hodgkin's type.42,74,78,IQl,219 
This feature appears to be shared among several of the Herpes vi-
ruses, since Herpes lymphadenitis may, on occasion, also mimic 
lymphoma? 
The term posttransplant lymphoproliferative disorder is used to 
refer to a spectrum of entities that merge into the histologic pattern 
of infectious mononucleosis on the one hand and the histologic pat-
tern of true non-Hodgkin's malignant lymphoma on the other. The 
relation of Hodgkin's disease to PfLD is uncertain at this time. Hodg-
kin's disease has uncommonly been reported in transplant 
recipients76, 187, 188 and is not increased in frequency in congenitally 
immunodeficient states.85 Likewise, the relationship of PfLD to the 
rarely occurring T-cell lymphomas in transplant patients is also un-
clear.132,162 
In essence, PfLD is an uncontrolled or poorly controlled prolifer-
ation of lymphocytes. The cells grow diffusely, often causing de-
struction of underlying structures. This appearance is subject to 
considerable modification dependent upon the balance between the 
state of tumor progression and host response. A full histologic report 
of PfLD should include evaluation of: (1) the nature of the growth 
pattern (diffuse, invasive, etc.); (2) the degree of necrosis; (3) the po-
lymorphic/monomorphic nature of the cells; (4) the presence or ab-
sence of plasmacytoid differentiation; and (5) the presence or ab-
sence of atypical mononuclear blast forms. The nodal or extranodal 
location of the tumor should be specified. The presence or absence 
of retention of underlying architecture should also be commented 
upon. 
A diffuse pattern of growth is characteristic of PfLD.90 Uncompli-
cated infectious mononucleosis involving lymph nodes usually 
shows a combination of diffuse areas and residual nodular areas, 
which represent germinal centers, although the latter may be appar-
ent only by the use of special stains.42 Much attention has been 
given to the differentiation of PfLD from garden variety malignant 
lymphoma. It may be equally difficult to distinguish PfLD from in-
fectious mononucleosis. The difference appears to be quantitative 
rather than qualitative and in the iatrogenically immunosuppressed 
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patient may be a matter more of academic than of clinical relevance. 
Necrosis is often a prominent finding of PTLD90 (Fig 3). Large areas 
of confluent necrosis may reflect the gross impression . In other 
cases individual cell necrosis predominates . The cause of necrosis is 
probably related to a combination of rapid cell growth, destruction 
of nutrient blood vessels by angioinvasive lymphoid cells, host im-
mune effector mechanisms, or lytic infection of some of the cells. 
Similar degrees of necrosis have been observed in some cases of 
XLP.19B The relative contributions of each of these factors and the 
possible existence of other mediators of tumor necrosis have not yet 
been evaluated. 
The main cellular constituent of the PTLD is the B-Iymphocyte. 
This cell normally varies in size and shape as it undergoes differen-
tiation . B-Iymphocytes at all stages of differentiation may be seen 
within a PTLD. The term polymorphic has been applied to charac-
terize the mixed appearance that may result from this phenome-
non.90 A polymorphic appearance is thus composed of small lym-
phocytes, small cleaved, large cleaved, small noncleaved, large 
FIG 3. 
Low power photomicrograph of PTLD demonstrates large areas of confluent necrosis (He-
matoxylin-eosin stain) . (From Makowka L, Nalesnik MA, Stieber A, et al: Control of post-
transplant Iymphoproliferative disorders and Kaposi's sarcoma by modulation of immuno-
suppression, in Good RA, Lindenlaub E (eds): Symposia Medica Hoechst. The Nature, 
Cellular, and Biochemical Basis and Management of Immunodeficiencies. Stuttgart-New 
York, FK Schattauer Verlag, 1987, pp 567-627. Reproduced with permission.) 
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noncleaved lymphocytes, immunoblasts, and plasma cells (Fig 4). In-
fectious mononucleosis, as may be expected, also produces a variety 
of B-lymphocyte forms. Few other entities demonstrate a diffuse pro-
liferation of such a wide range of B-Iymphocytes . 
In addition to the polymorphic display of B-Iymphocytes, large 
bizarre cells may be seen. These cells have been called atypical im-
munoblasts (Fig 5).90 They may resemble Reed-Sternberg cells, and 
similar cells have also been described in uncomplicated infectious 
mononucleosis.42, 74. 101,164, 172. 219. 249 In CsA-associated proliferations, 
such cells usually constitute a background finding in PTLD . They are 
often, but not always, seen in association with areas of necrosis, sug-
gesting that the appearance may represent a response of the cell to 
a toxic microenvironment. In patients who develop PTLD in associ-
ation with routine immunosuppression, such cells may occur in 
more abundant numbers and have been interpreted as malignant 
cells. Our own studies indicate that the cells have no prognostic 
significance in CsA-associated PTLDs. Further studies are required 
to clarifY the range of cells that constitute this histologic entity. 
The most important histologic feature, at least in CsA-associated 
PTLDs, is the distinction between monomorphic and polymorphic 
proliferation. The polymorphic mixture of lymphocytes at varying 
FIG 4. 
Representative polymorphic PTLD. In this high-power photomicrograph, the diffuse prolif-
eration of lymphoid cells shows considerable variation in size and shape. (Hematoxylin-
eosin stain). 
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FIG 5. 
Minimally polymorphic PTLD which was shown to be monoclonal by immunoglobulin gene 
rearrangement analysis. Inset: rare large and atypical-appearing lymphoid cells found 
within the tumor. (Hematoxylin-eosin stain. From Makowka L, Nalesnik MA, Stieber A, et 
al: Control of post-transplant Iymphoproliferative disorders and Kaposi's sarscoma by 
modulation of immunosuppression, in Good RA, Lindenlaub E (eds) Symposia Medica 
Hoechst The Nature, Cellular, and Biochemical Basis and Management of Immunodefi-
ciencies . Stuttgart-New York, FK Schattauer Verlag , 1987, pp 567-624 . Reproduced with 
permission. ) 
levels of differentiation was one feature that first led Frizzera to re-
alize that the lesions were not identical to non-Hodgkin's lym-
phoma.90, 1JO A polymorphic proliferation is also used as one distin-
guishing feature between uncomplicated infectious mononucleosis 
and non-Hodgkin's lymphoma 42 Conversely, the earliest report of 
PTLD from the Minnesota seriesJ69 stressed the monomorphic ap-
pearance of two cases. 
In our cases, the majority of lesions display a polymorphic pat-
tern. In a minority of tumors, however, all cells appear to be at the 
same level of maturation. This monomorphic appearance suggests a 
divergent stage in tumor development (Fig 6). The uniformity of cells 
is strong circumstantial evidence that a single clone has emerged 
from a polyclonal background due to an expression of those char-
acteristics conferring a selective growth advantage. The actual situa-
tion is slightly more complex and is considered below in the discus-
sion of the relationship of tumor cionality and histology. 
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FIG 6. 
Touch imprint preparation from a monomorphic PTLD . In this case, there is significant 
homogeneity in the appearance of the nuclei. Mitotic activity is apparent. Scattered mac-
rophages containing ingested material can also be seen (hematoxylin-eosin stain). This 
cervical tumor was monoclonal by immunophenotypic and immunogenotypic analysis. The 
patient is alive and well following local resection and reduction of immunosuppression. 
An appearance between that of the polymorphic and mono-
morphic conditions has been seen by us on several occasions. This 
appearance is seen in lesions containing a predominance of plasma 
cells and plasmacytoid cells. It may be seen in at least two separate 
settings. In the first case, a mature, diffuse plasma cell infiltrate may 
be seen in lymph nodes in association with more typical PTLD else-
where. It is not clear whether this benign-appearing infiltrate repre-
sents a reaction to infection elsewhere or the earliest manifestation 
of PTLD. In any case, this appearance should prompt a thorough 
evaluation for EBV infection and the presence of occult mass lesions. 
In the second instance, this appearance has been seen in associ-
ation with regression of lesions. It may be that regression in such 
cases is associated with maturation of a population of B lympho-
cytes. This plasmacytic appearance may be infiltrative and is accom-
panied by the residua of previous damage due to the lesion. The 
cells may be interpreted as signifying an inflammation at this point 
if read out of context. (The process of B-cell maturation in PTLD may 
represent a benign counterpart of multiple myeloma. In this latter 
disease, evidence has been presented to suggest the maturation of 
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monoclonal lymphocytes into plasma cells.173 In multiple myeloma, 
of course, the maturation is not associated with regression). 
Secondary microscopic changes may vary according to the loca-
tion of the tumor. In the gut, the overlying ulcer often shows intense 
overgrowth of bacteria. It is possible that antigenic stimulation by 
these microorganisms may confer a selective proliferative advantage 
upon cells with the appropriate antibody specificity. No studies have 
yet addressed this possibility. 
In solid organs, parenchymal necrosis may be seen in conjunction 
with tumor. In one of our cases, a moderate portal infiltrate was 
associated with almost complete hepatocellular necrosis. 
Our interpretation of CsA-associated PTLDs stresses the distinc-
tion between polymorphism and monomorphism as being of pri-
mary impor1ance. The first, and most widely used, classification sys-
tem, however, is that of Frizzera,9o who recognized a continuum of 
histologic disease in this syndrome. The spectrum delineated in his 
classification consists of nonspecific reactive hyperplasia, poly-
morphic diffuse B-cell hyperplasia, polymorphic B-cell lymphoma, 
and immunoblastic sarcoma. 
In this classification system, polymorphic diffuse B-cell hyperpla-
sia (PDBH) represents a diffuse and invasive proliferation of B-Iym-
phocytes at varying stages of development. Progression to poly-
morphic B-cell lymphoma (PBL) is heralded by the appearance of 
confluent (geographic) necrosis and atypical immunoblasts. Immu-
noblastic sarcoma is described as a terminal histologic stage of ma-
lignancy. 
In our opinion, we are describing the same histologic spectrum 
originally seen by Frizzera. We recognize both PDBH and PBL as pro-
gressive steps in this development, but lump them together as po-
lymorphous PTLD, since in our patients both forms are usually eas-
ily controllable by the same therapeutic approach. The immuno-
blastic sarcoma of Frizzera most likely corresponds to what we 
would call monomorphous PTLD. Since monomorphous PTLD may 
resemble non-Hodgkin's lymphoma other than immunoblastic sar-
coma, we prefer not to use this latter term indiscriminately. 
Clonal Composition of Posttransplant Lymphoproliferative Disorder 
The term PTLD as used refers to a range of nonclonal to clonal 
proliferations. The nonclonal proliferations are also referred to as 
polyclonal and the clonal tumors referred to as monoclonal. For 
most cell types, clonal lesions represent malignancies and nonclonal 
proliferations represent hyperplasias. With increased ability to de-
tect clonal components, these distinctions are becoming blurred in 
areas. However, they still remain useful generalizations. 
The earliest description of transplant lymphomas considered 
them to be non-Hodgkin's lymphomas and, by inference, clonal. 
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Geis, in 1978, first applied the term multiclonal to these prolifera-
tions.96 In 1979, a major collaboration among the Universities of Ne-
braska and Minnesota and the Karolinska Institute was initiated for 
the purpose of more fully analyzing these lesions.20o Out of this work 
came the discovery, based on immunocytochemical studies, that 
both clonal and nonclonal PTLDs existed. These workers integrated 
their findings by hypothesizing that an initial polyclonal prolifera-
tion provided the substrate from which a malignant monoclonal 
proliferation could emerge. A case report was later offered to dem-
onstrate the transition from (benign) polyclonal to (malignant) mon-
oclonal PTLD.losa 
A second set of studies was performed at Stanford University in 
1983 utilizing immunoglobulin gene rearrangement techniques of 
both heary and light chain genes. In this study of tumors arising in 
10 heart recipients, evidence of clonal rearrangements was found in 
each case.50 The utility of this technique was underscored by the fact 
that prior immunophenotypic analysis failed to make any determi-
nation of clonal status in nine of the cases. On the basis of these 
findings the investigators considered the tumors to be neoplastic 
from the outset. This conclusion regarding clonality was buttressed 
by the discovery of clonal gene rearrangements in eight specimens 
sent to Stanford from the University of Pittsburgh series in November 
1983. The Stanford researchers were unable to reconcile their find-
ings with the findings of others90,244 that early lesions may be non-
clonal at presentation. Further analysis of some of their patients who 
had multiple concurrent tumors indicated that each separate tumor 
constituted a unique monoclonal proliferation.45 In this study of five 
patients, individual cases had between two and six separate clonal 
proliferations. Only rarely did tumors at different sites demonstrate 
identical patterns. The authors favored the hypothesis that the mul-
tiple clones represented derivatives from a progenitor tumor, rather 
than separate independent primary tumors. The detection of differ-
ing clonal rearrangements led these investigators to apply the term 
"multiclonal" to the family of proliferations. Later work from the 
Stanford group focused upon clarification of this phenomenon in 
the more readily available non-Hodgkin's B cell lymphomas from 
nonimmunosuppressed patients. They first observed that a signifi-
cant minority of such cases also demonstrated several clones.159,234 
This appeared to challenge the concept that lymphomas are neces-
sarily monoclonal. A later study showed that an important mecha-
nism for this diversity, at least in some cases, is the ability of the B-
cell to undergo continuing mutations at certain regions of the im-
munoglobulin genes, even after having reached a neoplastic state.48 
These findings suggest, first, that the multiple tumors seen in such 
cases are probably derived from a progenitor clone and, second, that 
an active process of clonal selection (i.e., "survival of the fittest") may 
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be ongoing in established tumors. We have also detected multiple 
related clones from one case of multiple synchronous PTLDs in our 
series, suggesting that a similar mechanism may be operative in this 
disorder as well (Locker, unpublished observations, 1987). Multiple 
clonal as well as nonclonal EBV-associated tumors have also been 
described in a case of severe combined immunodeficiency syn-
drome (the "bubble boy" caseJ.227 Most recently, the Stanford group 
has acknowledged the probable existence of polyclonal PTLDs, but 
continues to stress that occult monoclonal components may be de-
tectable only by DNA gene rearrangement methodology.47 
The first major summary of the University of Pittsburgh PTLD ex-
perience appeared in the Spring of 1984.244 We documented the 
clonality of PTLDs in the first 17 patients in our series, based on 
immunocytochemical techniques. The immunoperoxidase studies 
were concurrently performed in Pittsburgh and at St. Mary's Medical 
School in London by Professor K. Porter. One of the authors (MN) 
vividly remembers how a long comparison of results tabulating the 
frequency of positively staining cells agreed number for number, al-
most perfectly, despite the fact that the procedures were performed 
almost 3,000 miles apm1, using different reagents, personnel, and 
laboratories. On the basis of these studies we concluded that both 
polyclonal and monoclonal PTLDs did indeed exist. 
We were also the first to report a somewhat unexpected, but sem-
inal, finding that a reduction of immunosuppression was capable of 
inducing regression in some monoclonal, as well as polyclonal, tu-
mor.244 Because of the pivotal nature of this observation in regard to 
the role of immune control mechanisms and even the ultimate def-
inition of malignancy, the results were greeted with some degree of 
skepticism.78 This doubt was in large part due to the uncontrolled 
nature of the clinical series and to the fact that clonal determina-
tions were based on immunocytochemical techniques and not the 
newly described and more sensitive gene rearrangement proce-
dures. 
We have since applied immunoglobulin gene rearrangement 
methodology to a number of cases in our series. The results have 
confirmed our initial observations. On the basis of a combined im-
munogenotypic and immunophenotypic analysis of lesions in our 
first 43 patients with PTLD, 28% had monoclonal tumors, 30% had 
polyclonal tumors, and 12% had separate clonal and non clonal le-
sions. Clonal determinations were inconclusive in the remainder 
due to insufficient tissue samples178 (Nalesnik et al., submitted). 
In one case in our series, clonal analysis of multiple tumors by 
evaluation of immunoglobulin gene rearrangement was comple-
mented by clonal analysis of the EBV genome205 (Locker et al., man-
uscript in preparation). PreliminaIY results suggest a primary clonal 
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proliferation of a cell that had not yet arranged its immunoglobulin 
genes. (Infection of pre-B cells by EBV has previously been docu-
mented to occur in uncomplicated infectious mononucleosis,28 but 
the earliest known B-precursor has already rearranged its immuno-
globulin genes).112 As the cell continued to mature, immunoglobulin 
gene rearrangement occurred and derivative clones developed as 
separate tumors. If this example holds up, it indicates that some 
lesions referred to as nonclonal, even by immunoglobulin gene rear-
rangement studies, may be clonal proliferations if the lymphocyte 
involved has not yet rearranged its immunoglobulin genes. However, 
in other cases in our series, separate clonal and nonclonal prolifer-
ations were obseIved within the same patients. A similar finding of 
clonal and non clonal proliferations has been reported in at least one 
case from the Minnesota transplant series.107 
One patient in our series appeared to have had a clonal popula-
tion existing within a polyclonal background. A similar situation ap-
pears to have been described in a patient with Wiskott-Aldrich syn-
drome.6 The authors of this report, in discussing their case, have 
also questioned whether the monoclonal component was necessar-
ily equated with malignancy.6 A separate study of another patient 
with this syndrome has documented the presence of two separate 
monoclonal B-cell tumors,65 further indicating the similar pathogen-
esis of lymphoproliferations arising in either congenital or acquired 
immune deficiency states. 
No difference in the transplant to tumor time interval was seen in 
our patient series when clonal and nonclonal lesions were com-
pared. This indicates that either some tumors begin as monoclonal 
and some as polyclonal lesions, or that a progression from poly-
clonal to monoclonal tumors occurs very rapidly in these patients. 
A progression of monoclonal to polyclonal tumor runs counter to 
current concepts of tumor progression and is extremely unlikely. In-
deed, we agree with Harris39 that the term polyclonal lymphoma78 
should be avoided as a designation for this pathologic entity. 
In contrast to our findings, Hanto et al.l08, 109 have observed a more 
clear-cut temporal segregation between patients who developed ei-
ther polyclonal or monoclonal disease under the influence of con-
ventional immunosuppression. In their series, patients with poly-
clonal disease presented, on the average, within 1 year after 
transplant and those with monoclonal disease presented at a mean 
time of 5.3 years after transplant. t07 
Karyotypic Analysis of Posttransplant Lymphoproliferative Disorder 
Given the similarities in the proposed pathogenetic mechanisms 
operative in both Burkitt's lymphoma and PTLD, one might hypoth-
esize that most if not all of the monoclonal PTLDs would exhibit the 
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8;14 translocation (or one of its variants) typical of Burkitt's lym-
phoma. Unfortunately, from a reductionist standpoint, this is not the 
case. Indeed, as far as we are aware, there is only one case of mon-
oclonal PTLD from our series that has demonstrated a reciprocal 
t(8;14) (Jaffe, Nakazato, manuscript in preparation). 
Intriguing karyotypic data on 6 of 22 patients have been 
presentedl0710B from the Minnesota series. One of these patients 
with a monoclonal tumor of the cervix showed a translocation be-
tween the short arms of chromosome 2 and 19 in all cells examined. 
Four months later, a metastatic tumor from this patient showed this 
same translocation with an additional second translocation between 
the long arms of chromosome 6 and 16. This suggests tumor pro-
gression over this time period with the development of a more ma-
lignant cancer. 
A second patient in this series presented with a polyclonal PTLD 
but demonstrated trisomy 3 in four of 14 cells examined. This was 
interpreted as representing the emergence of a monoclonal prolif-
eration of cytogenetically abnormal cells within an otherwise poly-
clonal tumor. Despite this worrisome feature, the patient survived 
with no evidence of disease following a course of acyclovir and a 
discontinuation of immunosuppressive therapy. Interestingly, this 
was the only patient of the series who was maintained on a CsA-
containing immunosuppressive regimen. 
A third patient, with a trisomy 14 in approximately 50% of cells in 
a polyclonal PTLD, did not fare so well. Despite a discontinuation of 
immunosuppression and the institution of antilymphoma therapy, 
this patient expired 15 months later with metastatic disease and 
sepsis. Initial immunosuppression included azathioprine, predni-
sone, antilymphocyte globulin, and local graft irradiation.B3 
A fourth patient of particular interest had separate monoclonal 
and polyclonal PTLDS.107 Both tumors displayed a normal karyotype. 
This prompted the authors to suggest that (a) polyclonal-to-mono-
clonal conversion actually preceded the appearance of cytogenetic 
abnormality or (b) the cytogenetic abnormality was not necessary for 
malignant transformation in this case.lOB We would consider that 
both of these possibilities may be operative in a given case. Based on 
our experience, monoclonal PTLDs may be seen in the absence of 
cytogenetic abnormalities. A monoclonal proliferation of this sort, 
however, might better be referred to as an "opportunistic cancer" or 
"conditional neoplasia" to emphasize the necessity for the presence 
of an immunocompromised host. Malignant transformation might 
better be used to refer to the fully developed malignant phenotype 
that is a necessary precondition for the onset of a true cancer in an 
immunocompetent individual. 
Tumor cell karyotype has also been used on occasion to docu-
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ment the host or donor origin of the PTLD. Most reported cases have 
shown tumor cells to arise from the host population.188, 189 However, 
in bone marrow transplant recipients, tumors may arise from either 
hose1 or donorlOo, 168, 222 cells. 
Recently, it has been found that many non-Hodgkin's B-cell lym-
phomas contain specific chromosome translocations.27o Transloca-
tions identical to these have not been described at this time in 
PTLDs. 
Oncogene E;xpression in Posttransplant Lymphoproliferative 
Disorder 
Studies of oncogenes or their products have not yet been reported 
from the major series of transplant-associated lymphoproliferative 
disorders. However, Brichacek et al.26 have reported interesting re-
sults in their study of 15 specimens derived from patients with fatal 
infectious mononucleosis or XLP. In this series, rearrangement of the 
c-myc gene was found in eight of the tissues. In addition to this, 
rearrangements of immunoglobulin heavy chain genes were also 
found, indicating the presence of clonal populations of cells. The 
implication is that monoclonal proliferations of B cells containing a 
c-myc rearrangement were found in some of these cases. What 
makes this tentative conclusion even more intriguing is the fact that 
all patients expired within 1 to 20 weeks following onset of symp-
toms. Thus, fatal infectious mononucleosis may be associated with 
the rapid emergence of monoclonal B-cell populations and onco-
gene abnormalities. (Rapid development of monoclonal EBV-associ-
ated tumor has also been described in the setting of congenital im-
munodeficiency. No evaluation of c-myc was reported from this 
case).29 
Locker et al. have looked for c-myc rearrangements in a number 
of our cases of PTLDs from the Pittsburgh series (manuscript in 
preparation). Positive results were found in two of 42 specimens an-
alyzed. Both cases had a monomorphic histology and were mono-
clonal. One tumor was present in an ascites form, studding the peri-
toneum and causing the death of the patient. The other tumor, 
which appeared to begin in the ileum, was stubbornly recurrent, did 
not respond to reduced immunosuppression, and finally required 
chemotherapeutic inteIvention for eradication. 
A caveat in the interpretation of such studies is the recent obser-
vation that the product of the c-myc gene may be abnormally ele-
vated in the absence of rearrangement or amplification of the gene.82 
Thus, these DNA studies may not be capable of detecting all cases 
in which the c-myc protein plays a role. Nevertheless, it is likely that 
further investigations in this area will yield results of both theoretical 
and practical importance. 
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Hypothesis for Pathogenesis of Posttransplant Lymphoprolijerative 
Disorder 
Our hypothesis for the pathogenesis of PfLD is an extension of 
the hypothesis of Bird1s for the case of lymphomas arising in trans-
plant recipients and is similar in large part to the sequences of 
events postulated by Purtil0201,202 for the case of lymphomas in XLP 
patients, by Filipovich et al.8S for lymphomas in naturally occurring 
immunodeficiencies, by Kleinl44 for the evolution of Burkitt's lym-
phoma, and by Cooper53,54 for the development of non-Hodgkin's 
lymphomas. 
The dual basis for the production of PTLDs in immunosuppressed 
patients is (1) imbalance in host control of EBV-driven lymphoproli-
feration and (2) events conducive to tumor progression occurring on 
a stochastic basis within proliferating lymphocytes. 
A simplified schema is depicted in Figure 7. In normal as well as 
in immunosuppressed individuals, EBV infection causes a polyclonal 
proliferation of B lymphocytes. This proliferation is normally con-
trolled in the host by a variety of means, including the induction of 
B-cell maturation and T-cell cytotoxic effects. If these mechanisms 
do not occur, the polyclonal proliferation may continue in an un-
controlled fashion and lead to the death of the host. 
In transplant patients, many cases of EBV infection are apparently 
controlled without incident. Rare cases show uncontrolled prolifer-
ation leading to a rapidly disseminated proliferation of lymphocytes 
in most organs. If the polyclonal proliferation is only partially con-
trolled, a "polyclonal PfLD" may result. The continuing proliferation 
of these cells favors a clonal selection process allowing overgrowth 
of a dominant clone. This dominant clone may emerge due to exter-
nal forces, or it may arise as a result of mutations within the cell 
itself. The events may be considered to represent "tumor progres-
sion" in either case. 
According to the rules of tumor progression, (a) the cells will be-
come more malignant with time and (b) independent tumors will 
progress independent~yK Therefore, although the events can be uni-
fied under the general heading of tumor progression, we may also 
expect multiple branch points in this process, resulting in divergent 
tumor clones with varying degrees of "malignancy." 
What are the implications of this model in the individual patient? 
Obviously, events favoring EBV lymphoproliferation over host control 
mechanisms will favor the development of either fatal infectious 
mononucleosis or PfLD. Primary versus secondary EBV infection, ov-
erimmunosuppression, and constitutional host immune defects 
likely contribute to this process. Reduction of immunosuppression, 
acyclovir, and even surgical resection would tend to counterbalance 
these forces. 
With the emergence of a monoclonal lesion, the battle shifts from 
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Hypothetical pathogenetic sequence of PTLD development. Epstein-Barr virus infects B 
lymphocytes (1), which proliferate in a polyclonal fashion (2). Early in the course of infec-
tion (i.e., infectious mononucleosis), the B-cells mature into plasma cells (3). These dis-
appear from the circulation, and residual B-Iymphocytes undergo "dispersal" (4) by a 
variety of host effector mechanisms, most notably by the actions of cytotoxic T lympho-
cytes. In a minority of patients unable to mount an effective host response (e.g., XLP 
patients), rapid dissemination may occur (5), leading to fatal polyclonal infectious mon-
onucleosis. Both of these pathways are also operative in transplant recipients. In addition, 
the polyclonal proliferation may undergo a process of clonal selection leading to a mono-
clonal proliferation (6). Some monoclonal proliferations may represent minimally deviant 
popUlations, since they are still responsive to host control mechanisms following a reduc-
tion of immunosuppression. The host probably controls the tumors by a reestablishment 
of the mechanisms normally operative in the control of infectious mononucleosis (7). With 
further tumor progression (8), the tumor may become unresponsive to reestablished host 
control mechanisms. Unresponsive monoclonal tumors may also conceivably arise directly 
from a polyclonal proliferation without gOing through an intermediary responsive phase 
(not shown). It is unknown whether further manipulations, for example, the induction of 
EBV membrane antigens on these cells, may make some of these tumors once again 
responsive to host control mechanisms (9).141.146 The progression of polyclonal to mono-
clonal appears to occur over a long period in conventionally immunosuppressed patients. 
However, in esA immunosuppressed patients, both polyclonal and monoclonal tumors 
occur rapidly after transplantation. This suggests either that the polyclonal to monoclonal 
progression is rapid, or that both responsive and nonresponsive monoclonal tumors may 
arise de novo following EBV infection (10). 
the host: virus struggle to the host: tumor interaction. The virulence 
of the particular tumor clone may play a decisive role from this 
point on. Unfortunately, it is difficult to make any a priori assess-
ment as to the degree of malignancy, because of the multiplicity of 
cellular events that may occur and the limited number of patients 
with these conditions. In our experience, however, tumors that are 
polymorphic and polyclonal or polymorphic and monoclonal are 
more likely to be responsive to reestablished host immune control 
mechanisms than are tumors that are monomorphic and mono-
clonal.We have not yet obseIVed any tumors that are monomorphic 
and polyclonal. These histopathologic distinctions are not absolute, 
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however, indicating the necessity for a clinical trial of reduced im-
munosuppression and medical/surgical support in order to evaluate 
the behavior of the tumor(s). 
The responsiveness of a monoclonal tumor suggests that (1) the 
tumor has a competitive growth advantage over other clones but is 
not yet fully malignant, or (2) the tumor is fully malignant but ex-
presses strong (viral?) antigens. Either of these possibilities would 
render the tumor susceptible to host immune defenses. With further 
tumor progression, the neoplasm escapes beyond the reach of the 
host immune controls. 
It has generally been assumed that a substantial period of time 
was needed for enough events to occur in order to allow the emer-
gence of a monoclonal proliferation from a polyclonal background. 
In the case of non-CsA regimens, monoclonal tumors do not occur 
until years after transplant whereas polyclonal proliferations occur 
much earlier. In the case of CsA immunosuppression, however, 
monoclonal proliferation may be seen very early after transplant. 
This suggests either a de novo monoclonal proliferation or the rapid 
emergence of a monoclonal tumor from a polyclonal background. 
Based on our hypothesis of the pathogenesis of PTLD, we con-
clude: 
1. Prevention of EBV infection would eliminate this form of 
PTLD. 
2. Polyclonal proliferations are technically benign lesions. 
Thus, control of these lesions can be effected by eliminating 
the stimulus for proliferation or by augmenting or correct-
ing the host immune control mechanisms. The use of acy-
clovir and reduced immunosuppression addresses both of 
these aims in the absence of a constitutional host defect. 
3. Additional influences, beyond EBV stimulation, cause the 
emergence of monoclonal tumors. Thus, antiviral therapy 
alone is ineffective in this form of disease. 
4. Some monoclonal tumors will, and some will not, respond 
to reestablished host immune control. The response is de-
pendent on the integrity of the host immune response, the 
degree of tumor progression toward malignancy, and the 
relative rates of tumor growth and tumor destruction. 
Therefore, response to therapy should be closely followed. 
5. Independent tumors will progress toward malignancy inde-
pendently. Therefore all tumors within a patient should be 
followed for response to therapy. 
In summary, this multistep scenario suggests that a graded form 
of therapeutic intervention be employed, beginning with reduced 
immunosuppression, administration of acyclovir, and control of lo-
cal complications. These measures are usually sufficient. Only those 
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cases that do not respond to such measures should be considered 
for more aggressive antilymphoma therapies. These points will be 
more fully presented under Clinical Considerations and Case Pre-
sentations, below. 
CLINICAL CONSIDERATIONS 
PATIENT POPULATION 
As of March 1987, 43 patients in the combined Pittsburgh-Denver 
transplant series were diagnosed as having PTLD. These included 29 
males and 14 females ranging in age from 1 to 62 years, with a mean 
age of 23 years. The 43 patients accounted for 1.7% of the total trans-
plant population at that time. There were 23 liver, 12 kidney, 5 heart, 
and 3 heart/lung transplant patients in the series. This constituted a 
relative frequency for PTLD of 2.2%, 1.0%, 1.8%, and 4.6% in the re-
spective organ allograft sUbpopulations. Earlier reports from our 
series244 initially suggested a much higher incidence in heart and 
heart/lung recipients, an experience which has not been supported 
with time?65 Despite this change, the overall incidence of PTLD at 
our institution has not changed significantly from earlier reports.215 
Forty-one of the 43 patients had received initial immunosuppres-
sion with various CsA-prednisone-containing regimens. The remain-
ing two patients received CsA later in their course. In addition to 
these drugs, 9 patients received OKT3, 4 received azathioprine, 3 re-
ceived ALG, 3 received azathioprine and OKT3, and 1 underwent 
thoracic duct drainage. Tissue matching was on a random basis, es-
pecially for nonrenal donors. 
TIME OF ONSET OF POS7TRANSPLANT LYMPHOPROLIFERATNE 
DISORDER 
It has been our experience165 and the observation of others12, 185, 193 
that PTLDs occurring in association with CsA-containing regimens 
occur more rapidly after transplantation than do those PTLDs that 
occur in non-CsA-immunosuppressed patients. The reason for this 
is unknown. However, it is interesting to speculate that it may be 
related to the interaction between drug and host immune response. 
Perhaps CsA is a more potent inhibitor of the host anti-EBV immu-
no surveillance system. In that case, it may allow more florid out-
growth of PTLDs at an earlier and more reversible stage of develop-
ment. Conversely, standard immunosuppressive regimens may allow 
a subclinical, "smoldering" lymphoproliferation over time. This scen-
ario would help account for the observation that early PTLDs occur-
ring in non-CsA immunosuppressed patients resemble infectious 
mononucleosis but that late PTLDs in these patients are solid tu-
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mol's. Such a temporal distinction is not seen in esA-immunosup-
pressed patients. 
The majority of the 41 patients in our series who initially received 
esA-containing regimens had tumor onset within 1 year after trans-
plant, with a median onset time of 4.4 months, and a range of 0.7-
26.2 months. Two other patients in our series who were initially im-
munosuppressed with azathioprine-containing regimens had tumor 
onset times of 68 and 162 months following transplant. Some pa-
tients initially immunosuppressed with esA were also given supple-
mental OKT3 or ALG. No difference in PTLD onset time was observed 
in these patients compared to the esA patients as a whole. Likewise, 
those patients who initially received esA regimens and were later 
given azathioprine had a tumor onset time identical to the general 
esA population. 
In the Minnesota series an infectious mononucleosis-like presen-
tation was seen at a mean time of 9 months after transplant. Presen-
tation with solid tumor occurred at a mean onset time of 5.3 years 
following fransplant. lOs All patients except one in this series were on 
non-esA-containing regimens. The one patient who received esA 
had a mononucleosis-like syndrome at 16 months after transplant. 
Perhaps the most graphic display of the effect that the immuno-
suppressive regimen exerts on the onset time to tumor comes from 
the Stanford series. Of 10 patients with PTLD, five received conven-
tional immunosuppression and five received CsA-containing regi-
mens. In the first group, the number of days between transplant and 
tumor were 935, 1,335, 1,487, 1,514, and 2,575, respectively.50 In the 
second group, these intervals were 99, 101, 122, 151, and 187 days. 
CLINICAL PRESENTATION 
The presenting symptoms are dependent upon the localization of 
the PTLD, the severity of the disease, and the existence of concur-
rent infection. Some patients may be entirely asymptomatic, indicat-
ing the need for the physician to maintain a high index of suspicion. 
As has been observed in other transplant series, a significant pro-
portion of patients present with signs and symptoms resembling in-
fectious mononucleosis. In this group, rapid progression of the pro-
liferation may lead to early complications such as respiratory 
compromise due to tonsillar hypertrophy. Emergency tracheostomy 
may be required in such cases. Although the most dramatic symp-
tomatology is referable to the head and neck region in the form of 
tonsillar enlargement, cervical adenopathy, and salivary gland en-
largement (due to intrasalivary gland lymphoproliferationJ, the dis-
order often extends beyond this region. Contemporaneous systemic 
manifestations may be subclinical or may be as innocuous as mild 
lymphadenopathy. Conversely, some patients presenting with pre-
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dominant head and neck disease may also harbor other, unsus-
pected tumors at presentation. 
In our series, approximately 25% of patients presented with gas-
trointestinal manifestations. These included acute abdomen due to 
perforation of a hollow viscus, pain, obstruction, or gastrointestinal 
hemorrhage. Gastrointestinal disease has not been prominent in 
other transplant series utilizing conventional immunosuppres-
sion/85 but has been noted with Burkitt's lymphoma, AIDS lympho-
mas, and in lymphoid tumors of XLP patients. The reasons behind 
these distribution differences are not apparent. 
A third category of clinical presentation constitutes a variable 
complex of signs and symptoms, having in common a predominant 
involvement of a single or few organs. Thus, individual patients may 
present with lung lesions, renal mass, prostatic obstruction, or other 
indicators of tumor localization. Frequently this process first mani-
fests in the allograft organ, where it may mimic rejection. In such 
cases, biopsy diagnosis may be the first indicator of PTLD. 
In non-CsA immunosuppressed patients, localization of PTLD to 
the CNS elicits the presenting symptomatology in a significant num-
ber of cases.39 Central nervous system involvement appears rare in 
CsA-immunosuppressed patients.18S In our experience, this type of 
involvement is seen only in the face of widely disseminated disease. 
However, in the Minnesota experience, cited above, 14% of patients 
had PTLD confined to the CNS.l08 If the increased incidence of CNS 
lymphomas in conventionally immunosuppressed patients were ex-
plainable wholly by the concept of the brain as an "immunologically 
privileged site, .. 93 then one must inquire why a similar localization 
of tumor is not seen in patients receiving CsA. 
Occasional case reports exist demonstrating the emergence of 
PTLD at the site of antilymphocyte globulin injection.55,70 Interest-
ingly, in one case,7° a nodule that formed at the site of injection 
remained at a small and stable size for 10 months, at which time it 
rapidly enlarged and was diagnosed as a reticulum cell sarcoma. 
Rarely, patients present with fulminant disease and multiorgan in-
volvement. The response of these patients to all therapies appears 
poor. It is not known whether this represents an extremely ad-
vanced tumor, delay in diagnosis, or a profound defect in the host 
immune system. Further studies are needed to clarify this point. 
In six of our 44 patients, the diagnosis of PTLD was first made at 
autopsy. These patients generally had multifocal disease in associa-
tion with other, severe opportunistic infections. 
Touraine et al.2S9,260 have observed that PTLD may be accompa-
nied in its early stages by abnormal serum electrophoretic patterns 
detectable by isoelectric focusing. This approach may form the basis 
of a means to screen for PTLD, especially in the first year after trans-
plant in CsA-immunosuppressed patients. However, the high false-
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positive rate of this technique259 indicates that it needs to be com-
bined with a test of greater specificity. 
ASSOCIATED INFECTIONS 
In keeping with the proposed etiologic cofactors of PTLD, sero-
logic evidence of EBV infection was observed in 40 of the 43 patients 
in our series?65 Primal}' EBV infections outnumbered reactivation in-
fections by a ratio of 2.3: 1. Ninety-four percent of patients under the 
age of 18 had primary, rather than reactivation, infection. Ho et al.121 
have emphasized the importance of primal}' EBV infection in this 
disorder. Our results are similar to those in other previously pub-
lished studies in which the oveIWhelming majority of patients had 
evidence of EBV infection.l1o•1ll The absence of EBV in some patients 
raises the possibility of other unknown predisposing factors. 
The presence of EBV within the tumor cells has also been repeat-
edly documented by the use of immunofluorescence methods to de-
tect EBNA or by the demonstration of the EBV genome within DNA 
extracted from the lesions.121 Again, rare cases are negative for EBV 
by these techniques?' 21 
Over half of the patient population had other concurrent infec-
tions at the time of PTLD diagnosis. Pneumocystis carin ii, Herpes 
simplex, and cytomegalovirus were the most frequently identified 
pathogens in these patients. This lends further support to the con-
cept that many of these patients are functionally overimmunosup-
pressed. These additional infections may also serve to cause further 
immunosuppression in the patients. 
CLINICAL COURSE AND THERAPY 
Twenty seven of the 43 patients in our series have demonstrated 
resolution of PTLD165 (Nalesnik et al., submitted). In 10 of these 27 
patients, reduction of immunosuppression (with administration of 
intravenous acyclovir in two cases) constituted the sole form of ther-
apy. Surgical intervention was limited to biopsy for diagnostic pur-
poses. Evidence of monoclonality was observed in four of these 10 
patients. Follow-up time ranges from 13 to 59 months in this group. 
The other 17 patients with resolution of PTLD had more aggressive 
surgical intervention due to either the size of the tumor or the pres-
ence of tumor-associated complications. Evidence of monoclonality 
was observed in seven of these 17 patients. Five of the 17 patients, 
including three with monoclonal disease, received additional 
chemotherapy or radiotherapy, or both. In retrospect, this interven-
tion may have been unnecessary in some cases. One of these pa-
tients, however, had multiple recurrences of tumor following resec-
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tions and discontinuation of immunosuppression. It was in this 
setting that chemotherapy was instituted. This case is presented in 
detail below (case 6). 
No response to therapy was seen in five of the 44 patients. These 
patients all had evidence of monoclonal tumors that were wide-
spread. One patient developed invasive aspergillosis following 
chemotherapy. Another had disseminated cryptococcosis, under-
scoring the severity of the immune defects. These patients often had 
delays in diagnosis and in therapeutic intervention, contributing to 
a complicated course. Nevertheless, these complications do not ne-
gate the fact that these malignancies led to the deaths of these in-
dividuals. 
In five patients, it is not possible to come to an unequivocal con-
clusion regarding tumor behavior. Two of these five appear to have 
had partially to nearly complete resolution of tumor but expired of 
related complications. In the other three patients, no significant 
therapeutic response was possible, and they expired shortly after 
diagnosis. The difficulty in using death as an endpoint in concluding 
that a tumor is not responsive to therapy is considered in the dis-
cussion of cases 4 and 7. 
Tumor was diagnosed at autopsy in six patients. All had evidence 
of other severe and mUltiple infections at that time. 
Several clinical features suggest a more favorable prognosis, on the 
basis of our patient series. In our experience, patients with tumors 
predominantly involving the gastrointestinal tract have an excellent 
prognosis with appropriate therapy. Over 80% of our patients with 
this form of disease are alive from 3 to 7 years after diagnosis. These 
tumors, usually multiple, can rapidly cause perforation, obstruction, 
or intussusception, all of which must be surgically relieved. 
A good prognosis is also associated with a predominantly head 
and neck presentation of PTLD (excluding CNS disease). These cases 
probably include a number of cases of infectious mononucleosis 
with minimal progression toward a full-blown PTLD. But some mon-
oclonallesions also may be seen in this area as well. Eleven of thir-
teen patients with this form of presentation have undergone resolu-
tion of their disease. 
A disseminated presentation of disease, often in association with 
other infections, was a poor prognostic indicator. These patients ex-
pired within a short period of time regardless of the form of therapy 
employed. Fortunately, this manner of presentation is uncommon 
and may be made even rarer by a high index of suspicion on the 
part of the physician, which will allow earlier diagnosis and treat-
ment of lesions before they progress to this stage. 
Conversely, limited organ involvement is often a treatable disease. 
Cases predominantly involving the lung or kidney appear to respond 
to conservative management as outlined above. Isolated CNS involve-
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ment was not seen in our series. However, in reports from other 
centers, this form of disease is associated with a poor prognosis. 
Pathologic studies may give additional useful information but 
must be interpreted in conjunction with the extent of disease. Poly-
morphic and polyclonal tumors are more likely to undergo regres-
sion than are monomorphic and monoclonal tumors, but the dis-
tinction is not absolute. More sensitive indicators such as the 
intensity of the rearranged monoclonal band on Southern blot and 
the presence of myc-oncogene rearrangement may allow better 
prognostication in the future (Locker J et al., unpublished report). 
For the present, the response of tumor to a clinical trial of reduced 
immunosuppression and administration of acyclovir remains a fa-
vored approach in planning subsequent management. 
Concern has been expressed over the reduction of immuno-
suppression in recipients of allografts other than kidneys, in which 
supportive therapy may not be available should organ rejection oc-
cur. In our opinion, PTLD is a manifestation of functional overim-
munosuppression, regardless of the absolute amount of drug given 
to the patient. In accordance with this, we have observed that a re-
duction of CsA by as much as 50% may often be employed with only 
a minimal to mild risk of organ rejection. 
Therefore, our initial therapeutic approach is to reduce immuno-
suppressive medications to about 50% of the baseline dose following 
the diagnosis of PTLD. The patient is then observed clinically for (1) 
evidence of regression of PTLD and (2) the possible emergence of 
allograft rejection. If necessary, we will further reduce or even dis-
continue immunosuppession depending upon the clinical course. 
In following allograft status by biopsy, care must be taken not to 
confuse rejection with PTLD. PTLD generally shows immunoblastic 
differentiation with plasmacytoid features, and large atypical cells 
can be seen on occasion. These features are lacking in the rejection 
response, which localizes to specific structures in specific organs. 
Simultaneously, the fate of the residual PTLD must be followed. This 
is best done radiologically, in addition to monitoring the patient 
clinically for the appearance of acute tumor complications. Clear evi-
dence of tumor regression should be seen within 2 weeks and usu-
ally is seen within a few days. If no changes are seen by this time 
period, it is still possible that cure may be effected by resection of a 
localized residual tumor. If the tumor continues to grow during this 
interval, these measures may prove inadequate and chemotherapy 
should be considered. However, the use of chemotherapy as a first 
line measure in these immunologically compromised patients is to 
be strongly discouraged. Our experience, as well as that of others,40 
shows that death from sepsis is a likely outcome in this setting. No 
center has successfully managed a large series of cases by the use of 
chemotherapy. In this regard we are no exception. Nevertheless, we 
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feel that C'hemotherapeutic intervention must take into considera-
tion (1) the initial immunosuppressed condition of the patient and 
(2) the often striking response of ElW-associated Burkitt's lymphoma 
to' minimally to moderately aggressive antilymphoma treatment. 
Assuming. that the patient has clinically responded to a therapeu-
tic regimen including reduced immunosuppression, a thorough 
evaluation for occult or recurrent tumors should be performed at 
i'nte'IVals. Following remission of PTLD we generally resume the pa-
tient on initial or slightIy reduced levels of immunosuppression. 
The' similarity of our approach to that of others is evident on the 
basis of scattered case reports. In one example, Bia and Flye13 doc-
umented regression of pulmonary tumor nodules that arose in as-
sociation with a multicentric, mono donal intestinal PTLD in a renal 
fransplant recipient immunosuppressed with esA and prednisone. 
'fhe intestinal tumor was resected, but the lung nodules were not 
excised. Monoclonality of the intestinal tUlliO'!!" was diagnosed by im-
munoglobulin gene rearrangement studies. esA was discontinued 
completely, resulting in allograft rejection. The lung, nodules disap-
peared totally and there is no evidence of recurrence to date, 43 
months after initial diagnosis (Bia, personal communication, 1987). 
Hanto et al.lOB.l09 stress the efficacy of acyclovir in alleviating PTLD 
classifed as polymorphic diffuse B-cell hyperplasia in which a poly-
clonal pattern is documented. In the presence of PTLD diagnosed 
as polymorphic B-celllymphoma, or with documentation of a mon-
oclonal component, they carefully increase their level of interven-
tion, including a reduction of immunosuppression. We feel that this 
is a reasonable approach but prefer to reduce immunosuppression 
as a first-line measure, usually with the addition of acyclovir. In this 
manner we do not risk allowing the continued proliferation of la-
tently infected cells.109.237 The price to be paid is the increased risk 
of organ rejection. However, we must emphasize that it is possible 
to titrate the reduction of immunosuppression in order to minimize 
and abort this risk of rejection. Incidently, we agree with Hanto108,109 
that organ rejection must occasionally be allowed to proceed in or-
der to gain the upper hand on the PTLD. An uncontrolled lympho-
proliferation in this setting will otherwise quickly cause the death of 
the patient. 
Bird and Britton, in an elegant review of EBV and lymphoma, had 
previously recommended a reduction of immunosuppression for 
treatment of polyclonal disease. They also raised the possibility that 
some monoclonal tumors may and some may not respond to this 
intervention. IS 
The 1978 report of Geis et al, is of interest, since it apparently 
describes regression in five cases of PTLD with no reduction of im-
munosuppression and with no antitumor therapy.96 However, tu-
mors in all of these patients arose in response to a particular lot of 
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anti-thymocyte globulin. When this drug was discontinued, there-
fore, a de facto reduction of immunosuppression did indeed occur. 
SPECIMEN PROCESSING IN SUSPECTED CASES OF 
POSTTRANSPLANT LYMPHOPROLIFERATNE DISORDERS 
The two purposes of surgical inteIVention in cases of suspected 
PTLD are (1) diagnosis and (2) management of complications (e.g., 
perforated bowel, respiratory obstruction). Often both purposes co-
incide. 
The full diagnosis of PTLD is dependent on a variety of histologic, 
immunophenotypic, virologic, and immunogenotypic techniques. 
Much information can be obtained from the histology alone. We do 
not, however, encourage the use of frozen sections for several rea-
sons: (1) a presumptive diagnosis of PTLD can usually be made ei-
ther by the clinical presentation or by the appearance of mass le-
sions at operation; (2) frozen sections destroy the fine histologic 
details of the tissue and in most cases will only support the surgical 
suspicion without offering any additional useful information (an er-
roneous overdiagnosis of malignant lymphoma is especially likely in 
this setting); (3) tissue may be more profitably divided for other stud-
ies. 
The surgeon should provide the pathologist with as much tissue 
as possible to perfornl adequate studies. Though trite, this dictum is 
of especial importance in this case. In cases of multiple tumors it is 
useful to provide specimens from as many tumors as possible. Due 
to the independence of tumor progression, separate lesions may 
have reached different levels of malignant transformation. 
The specimen should be provided fresh and sterile to the pathol-
ogist as soon as possible after resection. It should be kept moist with 
a small amount of sterile saline or, if at all possible, tissue culture 
fluid. Separate specimens should be submitted for culture, including 
viral culture. 
Once received from the surgeon, the specimen is further divided 
into aliquots by the pathologist. A small portion of sterile tissue 
should immediately be submitted for karyotypic analysis. There are 
several options of tissue processing for clonal and virologic analysis. 
Clonal analysis may be performed on frozen tissue sections or on 
cell suspensions by immunocytochemistry. Alternatively, tissue may 
be set aside for immunogenotypic analYSis of clonality. We prefer a 
combination of the two methods. Immunohistochemical analysis 
gives rapid results that may be sufficient in a number of cases, while 
immunoglobulin gene rearrangement analysis is a more sensitive in-
dicator of clonal composition. The latter technique, if available, usu-
ally has a prolonged turnaround time. 
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Alternative techniques are also available for demonstration of EBV 
within the tumor specimen. Immunohistochemical staining for Ep-
stein-Barr nuclear antigen (EBNA) may be performed on touch prep-
arations or, more satisfactorily, on frozen tissue sections. Detection 
of the EBV genome by DNA hybridization requires purification of 
DNA from the tumor. 
In practice, we usually freeze a portion of the specimen for the 
various immunohistochemical analyses and separately freeze a por-
tion of tissue for purification of DNA. Both clonal and virologic stud-
ies can be performed on both specimens if necessary. 
Following the allotment of tissue for these purposes, a portion of 
these is submitted for routine light microscopic analysis. We usually 
submit a minute fragment of tumor for electron microscopy but have 
not found this to be a useful adjunct to date. 
Other studies are dependent on the interests of the investigators. 
The results from routine histology frequently establish the diag-
nosis and determine whether the lesion is monomorphic or poly-
morphic. Analysis of EBNA determines the presence or absence of 
EBV within the lesion. Immunohistochemical analysis of clonality 
may show a clear-cut monoclonal lesion or a likely polyclonallesion, 
or frequently may be ambiguous or negative. 
In the presence of a positive EBNA stain, the genomic analysis of 
EBV DNA will almost always confirm the result. However, it is not 
uncommon for an EBNA-negative tumor to subsequently show pos-
itive results for the presence of EBV by the technique of EBV DNA 
hybridization. This is because of technical difficulties, especially an-
tigen lability, inherent in the performance of the EBNA test. 
Likewise, it has been our experience that a clear-cut monoclonal 
determination on immunohistochemistry will be confirmed by DNA 
studies. The surgeon should not be too surprised, however, if a tu-
mor initially thought to be polyclonal later shows a monoclonal 
component on the basis of Southern blot studies. By that time, how-
ever, the tumor will frequently have declared its clinical behavior 
one way or the other. 
CASE PRESENTATIONS 
Case 1.-This 2¥z-year-old female with biliruy atresia and a history of 
failed Kasai procedure underwent orthotopic liver transplantation on May 
10, 1984. Her postoperative course is shown in Figure 8. Recovery was pro-
longed due to ischemic liver damage; however the patient was discharged 
6 weeks after transplant in excellent condition. In mid-July she developed 
fever, malaise, cervical and inguinal adenopathy, and rapid tonsillar enlarge-
ment that required emergency tracheotomy due to upper respiratory im-
pairment. At that time, a tonsillectomy and inguinal lymph node biopsy 
were performed. The tonsils demonstrated a diffuse, polymorphic prolifer-
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FIG 8. 
Case 1: Clinical course of a 2'12-year-old female liver recipient who developed PTLD re-
sulting In acute upper airway obstruction and requiring tracheostomy, tonsillectomy, and 
reduction of immunosuppression. (From Makowka L, Nalesnik MA, Stieber A, et al: Control 
of post-transplant Iymphoproliferative disorders and Kaposi's sarcoma by modulation of 
immunosuppression, in Good RA, Lindenlaub E (eds): Symposia Medica Hoechst: The 
Nature, Cellular, and Biochemical Basis and Management of Immunodeficiencies. Stutt-
gart-New York, FK Schattauer Verlag, 1987, pp 567-624 Reproduced with permission.) 
ation of lymphocytes in all stages of development in association with large 
areas of necrosis and with large, atypical Reed-Sternberg-like cells. A diffuse 
plasmacytic proliferation with retention of underlying architecture was ob-
served in the inguinal node. A diagnosis of PTLD was given, and the process 
was judged polyclonal on the basis of immunoperoxidase stains for cyto-
plasmic immunoglobulins as well as immunoglobulin gene rearrangement 
studies. 
The patient's CsA was reduced from 15.5 to 7.75 mglkglday and predni-
sone from 10 to 5 mglday, and she received a full intravenous course of 
acyclovir. She recovered promptly and is currently well 40 months later, 
with normal hepatic function. 
Comment.-The rapid growth of the tonsils leading to respiratory 
embarrassment serves to underscore the clinical severity of the dis-
418 Curr Prabl Surg, June 1988 
ease. In this case, pathologic documentation of the "benign" nature 
of the proliferation came much later and did not influence the ther-
apeutic inteIVention, although it did SeIve to provide a logical basis 
for the resolution of disease. It is important to recall that acute air-
way obstruction may also be seen as a rare complication of other-
wise typical infectious mononucleosis.160 The preferred treatment in 
that circumstance consists of high dose steroids. Concern has been 
expressed over the long-term effect of this treatment?60 In the im-
munosuppressed patient we would express similar concerns, espe-
cially since this therapy may further exacerbate the underlying host 
immune imbalance. The concurrence of tonsillectomy, reduction of 
immunosuppression, and acyclovir does not allow a conclusion as 
to which maneuvers might have been sufficient and which superflu-
ous. However, in practice, judicious operation coupled with reduc-
tion of immunosuppression, with or without acyclovir, has become 
the preferred approach at our institution. 
Case 2.-This 3-year-old male received a liver transplant on August 7, 
1984, for treatment of liver failure due to homozygous <Xl-antitrypsin defi-
ciency. Eleven months later he was readmitted to Children's Hospital fol-
lowing a 5-day history of fever, decreased appetite, vague abdominal pain, 
and cervical adenopathy. Tonsils were also enlarged. A biopsy of a 2-cm left 
cervical node showed a minimally polymorphic proliferation with plasma-
cytic differentiation. Bands of necrosis were obselved. A diagnosis of PTLD 
was given. Immunoperoxidase studies were consistent with a polyclonal 
proliferation. However, later immunoglobulin gene rearrangement studies 
showed a monoclonal component to the proliferation. 
CsA was reduced from 19 to 12 mglkglday and prednisone from 7.5 to 5 
mglkglday. No acyclovir was given. Adenopathy and tonsillar enlargement 
resolved, and liver function tests remained normal. The patient remains 
well without evidence of disease 28 months after diagnosis. 
Comment.-This case is of interest because of the presensce of an 
unsuspected monoclonal component to the PTLD on the basis of 
DNA studies. Despite this, the disease resolved in association with a 
reduction of immunosuppression. It is likely that "tumor progres-
sion" had evolved to the point that a clone of cells had emerged 
from a nonclonal background. The presence of numerous plasma 
cells with a minimally polymorphic appearance suggests that the 
tumor cells retained the capacity to mature. Conversely, a minor and 
less differentiated component of the proliferation may not have been 
appreciated on pathologic examination. Although this patient's dis-
ease completely resolved with appropriate therapy, current hy-
potheses suggest that, if this proliferation had been allowed to con-
tinue, a more malignant cell clone refractory to host control 
mechanisms would have emerged. Acyclovir has the potential to in-
hibit polyclonal proliferations due to EBV but has no effect on the 
latent virus5Z often seen with clonal proliferations. Therefore the ef-
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ficacy of this drug as the sole therapeutic agent in this case, al-
though problematic, appears theoretically inferior to either a reduc-
tion of immunosuppression or a combination of acyclovir and 
reduced immunosuppression.77 
Case 3.-The patient was a 20-year-old male who received an orthotopic 
liver transplant on January 12, 1982, for treatment of liver failure secondary 
to chronic active hepatitis. Retrospective serologic studies showed a pri-
mary EBV infection between March 12 and August 16, 1982. He presented 
with cervical adenopathy on August 24, 1982. Pathologic sections were ini-
tially interpreted as nonspecific reactive hyperplasia. The appearance was 
that of a minimally polymorphic, diffuse, plasma cell proliferation with no 
necrosis and with retention of underlying lymph node architecture. Ep-
stein-Barr virus DNA was detected in the tissue as well. (Thus the lesion 
qualifies as an early form of PTLD). _ 
No treatment was administered. He presented elsewhere in November 
with gastroenteritis and was again discharged with no specific therapy. On 
December 4, 1982, he re-presented elsewhere with a 1-week history of se-
vere pharyngitis and odynophagia. He was treated for a staphylococcal ab-
scess but remained febrile, with a necrotizing tonsillitis and bilateral cervi-
cal lymphadenopathy. The patient sustained irreversible laryngospasm 
during a laIyngoscopic procedure and expired on December 14, 1982. At 
autopsy, polymorphic PTLD with necrosis was seen in the tonsils. Addition-
ally, plasmacytOid infiltrates were seen in several organs and in the colon, 
where they were associated with hemorrhagic ulcers. Clonal studies were 
inconclusive. 
Comment.-In contrast to the first !\VO cases, sustained lympho-
proliferation with clinical consequences was seen in this patient 
who was maintained on full immunosuppression. The histologic 
changes at autopsy appeared more advanced than those seen in the 
original lymph node biopsy. The infiltration of organs and presence 
of colonic ulcers indicate the systemic nature of this illness. Death 
in this case does not appear to be an indicator of malignancy, since 
it followed a diagnostic procedure. It is likely that the patient's dis-
ease was still reversible at this point had the proper measures been 
taken. Of course, recognition of the process at first presentation 
would have led to control of the disease at the outset. 
Case 4.-This 16-year-old male with Laurence-Moon-Biedl syndrome un-
derwent a renal transplant on December 12, 1982, for end-stage renal dis-
ease secondary to this disorder (Fig 9). He was discharged in good condi-
tion 4 weeks after transplant. On March 26, 1983, he re-presented with 
severe guaiac-positive diarrhea. While in the hospital he developed an acute 
abdomen secondary to a perforated hollow viscus. At laparotomy multiple 
tumors, involving the ileum and colon, were found. The gross appearance 
of tumors was similar to that shown in Figure 2. Three separate perforations 
were discovered. Pathologic examination led to the diagnosis of PTLD. Im-
munoperoxidase studies of multiple tumors showed 11 of 13 to be mono-
clonal. One regional lymph node was also involved by tumor. It was not 
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Case 4. Clinical course of a 16-year-old renal transplant recipient who developed multiple 
small bowel PTLDs with perforation, requiring emergency resection. In this 1982 case, 
immunosuppression was completely discontinued, and graft rejection was allowed to pro-
ceed. A second resection to'remove remaining tumors revealed marked regression of 
previously observed masses. (From Makowka L, Nalesnik MA, Stieber A, et al: Control of 
post-transplant Iymphoproliferative disorders and Kaposi's sarcoma by modulation of im-
munosuppression, in Good RA, Lindenlaub E (eds): Symposia Medica Hoechst: The Na-
ture, Cellular, and Biochemical Basis and Management of Immunodeficiencies. Stuttgart-
New York, FK Schattauer Verlag, 1987, pp 567-624. Reproduced with permission.) 
possible to remove all of the tumors at that time. Postoperatively the pa-
tient's esA was discontinued completely and his prednisone maintained at 
15 mglday. Five weeks later an allograft nephrectomy was performed due to 
intractable rejection. At that time the abdomen was again explored by the 
same surgical team, who noted with surprise that the tumors had either 
reduced in size or disappeared completely. They resected the only suspi-
cious area, near the site of primary anastomosis (Fig 10). The pathologists 
were unable to reach a definitive diagnosis and termed the process "multi-
ple nonspecific healing and chronic active ulcers." The microscopic ap-
pearance was one of mucosal epithelial regeneration and underlying fi-
brous repair. Scattered throughout was a moderately dense infiltrate of 
mature plasma cells. Immunoperoxidase studies, however, again revealed 
the individual lesions to be monoclonal. 
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FIG 10. 
Case 4. Representative remaining "tumors" of bowet resected following a period of dis· 
continuation of immunosuppression . Other intestinal tumors were removed several weeks 
earlier and had a gross appearance similar to that seen in Figure 2. Prior anastomotic site 
is seen in the upper right-hand corner of photograph. See text for detail s. 
The patient remains well 56 months after tumor diagnosis and is cur-
rently awaiting a new kidney . 
Comment.-This case is instructive in conceptualizing the basis 
for our approach to this disorder. It is obvious that the multiple 
bowel perforations could have led to death in this patient with mon-
oclonal tumors. Had the case ended here, the diagnosis of "malig-
nant lymphoma" would have seemed logical. However, rapid surgi-
cal intervention allowed the patient to survive this episode . Again, if 
all of the visible tumors had been removed, the argument could be 
made that this alone effected a cure . But in this case it was neces-
sary to leave tumors behind. The clinical resolution coincided with 
discontinuation of CsA and rejection of the kidney allograft . Histo-
logically, the cells had matured into plasma cells but retained their 
monoclonal nature. The bowel wall showed changes of tissue repair, 
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indicating that the process was resolving. The available evidence 
suggests that the tumor cells matured into plasma cells in associa-
tion with a reduction in cell mass (i.e., dispersion or destruction of 
cells). 
One may still argue that a case for tumor cell maturation cannot 
be made because two different sets of tumors were sampled at two 
separate times. That these resolving lesions were somehow different 
is unlikely in light of the clinical course. In addition, clonal studies 
of EBV205 and immunoglobulin genes from a similar case indicate 
that multiple gut lesions arose from a single clone that underwent a 
dysplastic form of maturation, resulting in multiple separate, deriv-
ative tumors (Locker et al., unpublished observation, 1987). Yet a 
third case with a similar related clinical course provided several gut 
tumors following a period of reduced immunosuppression. In this 
instance one tumor showed cell maturation and a second resembled 
the original tumor and did not show maturation. However this sec-
ond tumor was associated with extensive necrosis and contained a 
small lymphocytic infiltrate that may have represented a cytotoxic 
host immune response. It is thus likely that there are several mech-
anisms by which tumor regression may be effected. 
From a clinical standpoint, this case illustrates the coordinated 
use of surgery and modulation of immunosuppression to control 
local complications and cause tumor regression. Because of the of-
ten explosive growth of these lesions, life-threatening disorders of 
this type may arise before the host can mobilize defenses against 
the tumors. Such complications should be handled expeditiously 
and are not to be construed as evidence that the lesion is intrinsi-
cally unresponsive to host immune controls. 
Case 5.-A 43-year-old white male received an 0I1hotopic liver transplant 
for treatment of liver failure secondaI}' to Laennec's cirrhosis (Fig 11). His 
postoperative course was complicated by severe renal failure, fungemia, and 
multiple episodes of rejection. He eventually recovered from all of these 
problems and was discharged with good hepatic and renal function. 
Six months after transplant, the patient was admitted elsewhere with a 
productive cough and dyspnea. Pneumocystis pneumonia and dissemi-
nated cytomegalovirus infection were diagnosed (Fig 12). esA was discon-
tinued (5.5 to 0 mg/kg/day) and prednisone was decreased from 7.5 to 5 mg/ 
day. Trimethoprim therapy and respiratory support were also administered. 
His condition improved except for the presence of a persistent nodular in-
filtrate in the lungs (Fig 13). An open lung biopsy was performed and re-
vealed a monomorphous PTLD. Immunosuppression was completely dis-
continued, and the lesions completely disappeared. He was discharged on 
low maintenance immunosuppression and is alive and well with good liver 
function and no evidence of disease 18 months after PTLD diagnosis (Fig 
14). 
Comment.-Cases 4 and 5 show regression of lesions that were 
clinically much different from those in cases 1-3. It may be argued, 
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Case 5. Clinical course of a 43-year-old male liver transplant recipient who presented with 
pneumocystis pneumonia, generalized cytomegalovirus infection, and respiratory failure. 
Pulmonary PTLD was diagnosed by open lung biopsy. (From Makowka L, Nalesnik MA, 
Stieber A, et al: Control of post-transplant Iymphoproliferative disorders and Kaposi's sar-
coma by modulation of immunosuppression, in Good RA, Lindenlaub E (eds): Symposia 
Medica Hoechst: The Nature, Cellular, and Biochemical Basis and Management of Im-
munodeficiencies. Stuttgart-New York, FK Schattauer Verlag, 1987, pp 567-624. Repro-
duced with permission.) 
probably correctly, that the first several cases represent nothing 
more than severe infectious mononucleosis and therefore the treat-
ment of these patients in no way applies to the treatment of trans-
plant patients with "malignant lymphomas." Case 4 was shown to 
be monoclonal by immunophenotype. Case 5 is most likely mono-
clonal because of our finding that all monomorphic PTLDs in which 
clonality has been determined have been monoclonal to date. The 
observed regression of these lesions suggests that tumor progression 
of PTLDs contains an intermediate zone composed of monoclonal 
tumors that are still responsive to host control mechanisms. A sep-
arate case of a monomorphic and monoclonal PTLD occurring in the 
lung of a heart/lung recipient (not presented here) was also observed 
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FIG 12. 
Chest x-ray of case 5, showing severe white-out of the lungs due to Pneumocystis, CMV, 
and PTLD 
by us. This case, which contained a monoclonal component by im-
munogenotypic analysis, also regressed under the influence of re-
duced immunosuppression. Some time later, however, it recurred at 
the site of the tracheal anastomosis. Again, reduction of immuno-
suppression resulted in a complete remission, which continues to 
date. 
The presence of a PTLD in the face of multiple pulmonary infec-
tions, seen in case 5, is not uncommon and suggests that some de-
gree of association may exist between these conditions. On the other 
hand, they may both simply be the result of a functionally overim-
munosuppressed state. 
Case 6.-A 4-year-old white male underwent orthotopic liver transplan-
tation on January 14, 1984, for treatment of biliary atresia (Fig 15). Immu-
nosuppression consisted of esA and prednisone. On February 5, 1986, the 
patient presented with 2 days' symptoms of appendicitis. At laparotomy a 
distal small bowel obstruction due to tumor was discovered. This was re-
sected with a primary ileocolic anastomosis. A pathologic diagnosis of mon-
oclonal IgM lambda PTLD was rendered and the patient was taken off all 
immunosuppressive medications for 6 days. Thereafter he was restarted on 
esA 2.5 mgJkgJday and prednisone,S mg four times a day. Postoperative 
abdominal computed tomography (eT) scan revealed small periaortic 
lymphadenopathy. 
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FIG 13. 
Case 5. Continuing multinodular infiltrates in this patient led to open lung biopsy and 
diagnosis of PTLD. (From Makowka L, Nalesnik MA, Stieber A, et al : Control of post-
transplant Iymphoproliferative disorders and Kaposi's sarcoma by modulation of immuno-
suppression , in Good RA, Lindenlaub E (eds): Symposia Medica Hoechst: The Nature, 
Cellular, and Biochemical Basis and Management of Immunodeficiencies. Stuttgart-New 
York. FK Schattauer Verlag, 1987, pp 567-624 Reproduced with permission.) 
In May he presented with an epigastric mass, and an abdominal CT scan 
showed a midabdominal tumor mass 8 cm in diameter (Figs 16 and 17J. CsA 
was discontinued at this time, but prednisone was continued at 5 mg four 
times a day. A repeat scan in June showed no change in the size of the 
mass. Upper GI series with small bowel follow-through was consistent with 
an extraintestinal mass. A CT-directed percutaneous needJe biopsy again 
revealed monoclonal IgM lambda PTLD. Bone marrow biopsy was negative 
for tumor. All immunosuppression was discontinued in July 1986. 
On September 2, 1986, the patient was readmitted. Computed tomogra-
phy scan revealed multiple abdominal mesenteric masses with no abnor-
malities in the chest or neck. Debulking of omental tumor and biopsy of 
allograft liver were performed on September 11. A pathologic diagnosis of 
IgM lambda monoclonal malignant lymphoma was rendered. Cellular rejec-
tion with no evidence of tumor infiltration was found in the liver biopsy. 
The tumor again recurred and required debulking by February 1987. The 
histologic appearance was similar to that of previous resections. In July 
1987 tumor had again recurred. It was decided to utilize antilymphoma 
chemotherapy to eradicate the lesion. To date, the patient has remained 
free of tumor and has not had resumption of chemotherapy. A more de-
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FIG 14. 
Case 5. Chest x-ray prior to discharge showing complete resolution of PTLD. (From Ma-
kowka L, Nalesnik MA, Stieber A, et al : Control of post-transplant Iymphoproliferative dis-
orders and Kaposi's sarcoma by modulation of immunosuppression , in Good RA, Linden-
laub E (eds): Symposia Medica Hoechst. The Nature , Cellular, and Biochemical Basis 
and Management of Immunodeficiencies. Stuttgart-New York, FK Schattauer Verlag, 
1987, pp 567-624. Reproduced with permission ) 
tailed case report of this patient, who also had episodes of hypercalcemia 
in relation to the tumor, is underway (Jaffe R, Nakazato et al., unpublished 
report ). 
Comment.-In this instance, the tumor did not respond to multi-
ple attempts to induce regression by means of reducing immuno-
suppression. A short trial of acyclovir was also ineffective in this re-
gard (Nakazato) personal communication, 1987). That the tumor did 
indeed represent multiple recurrences and not new primary lesions 
was proven by the identical immunophenotype of each lesion and 
by the identical immunoglobulin gene rearrangement pattern dem-
onstrated by Southern blotting of the separate tumors (Locker) per-
sonal communication) 1987). 
On further analysis, the tumor showed a translocation involving 
the long arms of chromosomes 8 and 14 in association with myc-
oncogene translocation (Locker, personal communication, 1987). 
This may represent a more advanced stage of tumor progression, in 
which the clonal proliferation has more completely liberated itself 
from dependence on host factors for growth. The c-myc transloca-
tion mayor may not be related to the ability of the tumor to escape 
immune control mechanisms. The tumor also demonstrated re-
duced Class II MHC antigen expression by flow cytometry.165 Defec-
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Case 6. Clinical course of a 4··year-old male liver transplant recipient who presented with 
PTLD of the terminal ileum and sustained multiple recurrences. (From Makowka L, Nales-
nik MA, Stieber A, et al: Control of post-transplant Iymphoproliferative disorders and Ka-
posi's sarcoma by modulation of immunosuppression, in Good RA, Lindenlaub E (eds): 
Symposia Medica Hoechst: The Nature, Cellular, and Biochemical Basis and Manage-
ment of Immunodeficiencies. Stuttgart-New York, FK Schattauer Verlag, 1987, pp 567-
624. Reproduced with permission.) 
tive (Class I) MHC expression has been noted in some cases of gar-
den variety B-cell lymphoma 175 and might conceivably contribute to 
reduced B-cell interaction with regulatory T-cells. We currently have 
no hard proof for this speculation. 
In any event, it is apparent that a simple reduction of immuno-
suppression was not successful in this case even when combined 
with surgical resections, albeit incomplete. It is therefore prudent to 
monitor patients for signs of persistent tumor recurrence or progres-
sion throughout therapy. With this approach one will observe re-
sponses in the majority of patients who have noncIonal or regressi-
ble monoclonal lesions. These immunosuppressed individuals will 
thus be spared the burden of chemotherapy or radiotherapy. The 
few patients who do not respond to this regimen will at least have 
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FIG 16. 
Case 6. Small bowel study to investigate the first appearance of recurrent PTLD in the 
epigastrium. The small bowel is displaced by a large anterior epigastric mass (arrows), 
but no invasion of the small bowel mucosa is seen. (From Makowka L, Nalesnik MA, Stie-
ber A, et al: Control of post-transplant Iymphoproliferative disorders and Kaposi's sarcoma 
by modulation of immunosuppression, in Good RA, Lindenlaub E (eds): Symposia Medica 
Hoechsl .· The Nature, Cellular, and Biochemical Basis and Management of Immunodefi-
ciencies . Stuttgart-New York, FK Schattauer Verlag, 1987, pp 567-624 . Reproduced with 
permission.) 
had a chance to partially reconstitute their immune defenses prior 
to undergoing more aggressive antitumor therapies. 
In addition to case 3) the following two cases will serve to empha-
size the tragic consequences of delayed recognition and therapy of 
PTLD: 
Case 7.-This 15-year-old female underwent an orthotopic liver trans-
plant on February 20, 1972, for chronic aggressive hepatitis. Following the 
operation, the patient did well on prednisone and Imuran. 
In April 1985 she developed fever and sore throat and became jaundiced. 
No specific therapy was given, and elevated liver enzyme levels apparently 
dropped spontaneously. She was readmitted on May 23, again for fever and 
sore throat. She was thought to have rejection on the basis of a liver biopsy 
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FIG 17. 
Case 6. CT appearance of the epigastric mass depicted in Figure 21, further defining a 
large, solid, noninvasive mass anteriorly in the epigastrium. CT studies proved to be an 
excellent method of following this lesion. (From Makowka L, Nalesnik MA, Stieber A, et al: 
Control of post-transplant Iymphoproliferative disorders and Kaposi's sarcoma by modu-
lation of immunosuppression, in Good RA, Lindenlaub E (eds): Symposia Medica Hoechst: 
The Nature, Cellular, and Biochemical Basis and Management of Immunodeficiencies. 
Stuttgart-New York, FK Schattauer Verlag , 1987, pp 567-624 . Reproduced with permis-
sion.) 
and was given a steroid bolus. esA, 200 mg twice a day, was added to Imu-
ran, 50 mg four times daily, and prednisone, 10 mg four times daily. She 
later developed adenopathy and in early June immunosuppression was ta-
pered. A tonsillectomy done in the presence of coagulopathy led to acute 
respiratory failure and death on June 12, 1985. At autopsy, polymorphous 
and polyclonal PTLD was widely disseminated, involving the tonsils, lymph 
nodes, entire gut, thymus, allograft liver, kidneys, pancreas, salivary glands, 
lungs, adrenals, ovaries, and central and peripheral nervous systems. 
Comment.-In retrospect, the patient's disorder began at least as 
early as April, in association with a serologically diagnosed primary 
EBV infection. Immunosuppressive medication was continued and 
increased even more for treatment of presumed rejection . This al-
lowed the continued proliferation of the PTLD, Tapering of immu-
nosuppression was begun only during the last week of the patient's 
life, 
It may be argued that the direct cause of death was a technical 
complication of tonsillectomy. However, the massive tumor load 
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seen at autopsy is strong evidence that the patient was in a marantic 
condition for which continued therapy of any type was doomed to 
failure. 
The tumors in this case were nonclonal, indicating that techni-
cally "benign" populations of B-Iymphocytes were proliferating un-
controllably due to lack of host inhibitory mechanisms. This hypoth-
esis fits in well with the clinical course, in which the patient's 
immune system was effectively handcuffed by increases in antirejec-
tion medications. Several outcomes are possible in this setting: (1) 
uncontrolled proliferation of cells will occur, as in this case. There 
appears to be a "point of no return" beyond which the sheer over-
whelming mass of this proliferative process overwhelms all host de-
fenses and leads to death from any of a variety of immediate causes. 
(2) Proliferation of B-cells results in a genetic "accident" which 
causes the emergence of a single malignant clone. This clone quickly 
overgrows all others, leading to the death of the patient from mon-
oclonal disease. (3) The multifactorial attack on the host's immune 
system favors the growth of opportunistic organisms, and the pa-
tient dies from a combination of tumor and infection. 
It is apparent that these unfortunate conditions can only be pre-
vented by an adequate index of suspicion and early diagnostic and 
therapeutic intervention. 
In passing, it should be noted that the main immunosuppressive 
agent used in this case was Imuran, not cyclosporine. Two patients 
in our series who developed PTLDs received Imuran as the main 
immunosuppressive agent. Tumors in these patients arose at 68 and 
163 months after transplant. In CsA-immunosuppressed patients, 
the mean time to onset is less than 6 months. 
Case 8.-This 8-year-old female received an orthotopic liver transplant on 
November I, 1982, for treatment of a hepatic inflammatory pseudotumor. 
She developed infectious mononucleosis in association with primary EBV 
infection in July 1984. Over the next 6 months she had problems with re-
current upper airway obstruction and in December 1984 underwent tonsil-
lectomy and adenoidectomy for relief of this condition. Histologic changes 
were consistent with PTLD. The lesion was polymorphic and nonclonal. 
Over the next 6 months there was concern because of poor linear growth; 
however no cause for this could be found. In October 1985 her CsA was 
reduced from 250 mg four times daily to 200 mg four times daily because 
of azotemia. From October through December she had been seen on several 
occasions by her local pediatrician because of recurrent unexplained fevers. 
These were diagnosed ~ viral illnesses and spontaneously defeIVesced after 
a few days. Immunosuppression dosages remained unchanged. 
On December 17, 1985, she was admitted to Children's Hospital of Pitts-
burgh because of renal failure. At this time an enlarged left axillary lymph 
node was found. A bone marrow examination showed erythrophagocytosis 
consistent with viral infection. 
PTLD was suspected by the transplant surgeons, and CsA was reduced 
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by 50%. Acyclovir was also administered. On December 27, her CsA was 
increased to its previous levels because of suspected liver rejection. Dosage 
remained at this level until January 4, when it was discontinued. A lymph 
node biopsy revealed a monomorphous PTLD. The patient's condition rap-
idly deteriorated, and she developed pericardial tamponade. Tissue from a 
pericardial window revealed a similar infiltrate of monomorphous PTLD. 
Tumor growth progressed clinically, and on January 24 chemotherapy was 
begun. Six days later the patient developed ecthyma gangrenosum, and bi-
opsy showed tumor infiltration in association with aspergilli. The patient 
expired the following day. 
At autopsy, invasive aspergillosis due to A. jlmT(1s was found to involve the 
brain, heart, lungs, kidneys, intestines, and urinary bladder. Obstructive 
thrombi due to fungus were also found in the pulmonary arteries and cor-
onary vessels. Monomorphous PTLD was found to involve the allograft liver, 
kidneys, lymph nodes, bone marrow, heart, entire gut, pancreas, ovary, pi-
tuitary, thymus, parathyroid, lungs, adrenals, submaxillary gland, skin, and 
dura. 
Comment.-This case bears many si larities to the previous case. 
In this instance, there was a polyml ~hic PTLD that preceded a 
more aggressive, malignant lesion by 2 years. During this interval 
there was clinical evidence of continuing infection, manifest first by 
adenoid/tonsillar hypertrophy and later by recurrent viral syn-
dromes. It is most likely that a smoldering, low-grade proliferation 
of B-Iymphocytes continued during this time. The time sequence, 
although unusual in our series, fits very well with that described by 
Hanto et al.107 for similar lesions in non-CsA-immunosuppressed pa-
tients. They observed that early cases resemble infectious mononu-
cleosis and later cases resemble solid tumors. In contrast, this dif-
ference is not seen in the majority of our patients, most of whom 
present early. 
It is likely that an undefined host defect in this patient resulted in 
an inability to handle the virus appropriately. Therefore, the recur-
rent viral syndromes reflected an incubation period during which a 
monoclonal lesion could emerge. The relationship of the emergence 
of this tumor to the reintroduction of full-dose CsA during the final 
hospitalization cannot be defined with certainty. However, it most 
certainly favored tumor growth over host response, and in that sense 
accelerated the course of the disease. The use of chemotherapy re-
sulted in severe invasive aspergillosis, which, coupled with tumor, 
was the immediate cause of death. 
Since the presumed constitutional host defect in this patient is 
undefined, it is possible that the eventual emergence of a clonal tu-
mor could not have been prevented. To date, this phenomenon has 
not been observed in any other patient in our series. With our pres-
ent knowledge, however, it is still likely that earlier diagnosis, cou-
pled with a therapeutic trial of reduced immunosuppression and, if 
necessary, earlier chemotherapy, could have eradicated tumor in 
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this patient. The impression that early diagnosis is crucial for suc-
cessful treatment of PTLD has also been expressed by others.259 
CASE REPORT OF KAPOSI'S SARCOMA IN A RENAL 
TRANSPLANT RECIPIENT 
INTRODUCTION 
Kaposi's sarcoma (KS) is rare tumor normally seen in limited geo-
graphic areas.74a The etiology of this tumor is unknown; a causative 
role for cytomegalovirus is far from proven. It may present as pur-
plish, raised, firm and nontender skin lesions. Alternatively, it may 
present in a more widespread form involving lymph nodes, gastroin-
testinal tract, or lungs. Whereas skin lesions are generally asympto-
matic, gastrointestinal involvement may cause hemorrhage, pain, 
nausea and vomiting, or other symptoms. The diagnosis is made by 
biopsy, which classically shows a spindle cell neoplasm with slit-like 
spaces containing numerous erythrocytes. Small lesions can be re-
sected or treated by local radiotherapy, whereas several chemother-
apeutic regimens are available for more disseminated forms of the 
disease. 
The increase of KS in AIDS patients is well known.43 Similar in-
creases of KS have been seen in immunosuppressed transplant re-
cipients. The frequency of this lesion in the transplant population is 
much less than that of PTLD. Nevertheless, it comprises a total of 
about 8% of tumors in transplant recipients immunosuppressed 
with esA-containing regimens, compared to 3% of all tumors in con-
ventionally immunosuppressed patients.185,193 In our series, KS is 
seen at an overall frequency of only 0.1%.165 Additionally, the cases 
in our series have all occurred in Saudi Arabian males. 
The regression of KS in transplant recipients following reduction 
or discontinuation of immunosuppression has been previously re-
ported.190 For reasons that are not clear to us, this phenomenon ap-
pears to have met with much more acceptance in the medical com-
munity than has the similar behavior of PTLD. Perhaps this is so 
because there is some question as to whether or not KS even is a 
neoplasm. An intriguing proposal suggests that it may simply rep-
resent a hyperplastic proliferation.z7a 
On the basis of our experience with PTLD, we suggest that a sim-
ilar spectrum of tumor progression may also exist for KS. Because of 
the limited number of cases, lack of molecular probes for clonality, 
and lack of evidence for a histologic progression similar to PTLD, all 
cases are subsumed under the heading of KS. Based on our experi-
ence with PTLD, we would expect that the majority of cases of KS 
would resolve with judicious management and the reduction of im-
munosuppression. The possibility exists that a malignant counter-
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part of this lesion may develop in transplant patients, if sufficient 
mutations occur in the proliferating cells . The full spectrum of these 
disorders remains to be delineated. 
CASE REPORT 
This 35-year-old Saudi Arabian male received a cadaver kidney transplant 
for treatment of end-stage renal disease. Posttransplant complications in-
cluded schistosomiasis of the bladder and epididymitis, both of which re-
sponded to therapy. Six months following transplant he developed pur-
plish, raised skin lesions around the transplant scar (Fig 18). These spread 
to the upper trunk and arms. The diagnosis of KS was made on skin biopsy. 
He developed severe gastrointestinal symptoms and on radiologic exami-
nation was found to have diffuse involvement of the GI tract (Figs 19 and 
20). Endoscopic biopsy of the stomach confirmed the presence of KS 1 65 
Immunosuppressive therapy was discontinued, leading to a rapid reso-
lution of the lesions, espeCially in the gastrointestinal tract. An attempt to 
restart low dose immunosuppressive therapy led to a rapid reappearance 
of skin and gastrointestinal lesions. Thus, CsA and prednisone were again 
discontinued, resulting in a resolution of the recurrent lesions. 
Although the patient has retained his kidney for approXimately 1 year, 
FIG 18. 
Kaposi 's sarcoma in a renal transplant reCipient. The skin lesions of Kaposi's sarcoma can 
be seen in conjunction with the transplant scar. (From Makowka L, Nalesnik MA, Stieber 
A, et al: Control of post-transplant Iymphoproliferative disorders and Kaposi's sarcoma by 
modulation of immunosuppression, in Good RA, Lindenlaub E (eds) : Symposia Medica 
Hoechst.' The Nature , Cellular. and Biochemical Basis and Management of Immunodefi-
ciencies. Stuttgart-New York, FK Schattauer Verlag , 1987, pp 567-624 . Reproduced with 
permission .) 
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FIG 19. 
Small bowel series demonstrating diffuse widespread involvement of GI tract with biopsy-
proven Kaposi's sarcoma. Arrows demonstrate thickened mucosal folds due to tumor. 
(From Makowka L, Nalesnik MA, Stieber A, et al: Control of post-transplant Iymphoprolifer-
ative disorders and Kaposi's sarcoma by modulation of immunosuppression, in Good RA, 
Lindenlaub E (eds): Symposia Medica Hoechst.· The Nature, Cellular, and Biochemical 
Basis and Management of Immunodefictencies . Stuttgart-New York, FK Schattauer Ver-
lag, 1987, pp 567-624. Reproduced with permission.) 
renal function studies indicate slow and progressive rejection. He remains 
well with no evidence of gastrointestinal lesions but with minimal skin le-
sions (Fig 21). 
COMMENT 
Again we see a dramatic response of the host-tumor unit following 
modulation of the immune response. Kaposi's sarcoma, which arose 
in this patient follOwing a disabling of the immune response by esA 
and prednisone, regressed when the cells were allowed to resume 
their normal functions. The persistence of minimal skin lesions in-
dicates that the final verdict on this case is not yet in. From a clinical 
standpoint, however, it is obvious that the patient would have ex-
pired with tumor had not the appropriate actions been taken. There-
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FIG 20. 
Close-up of small bowel series, demonstrating prominent folds in stomach Infiltrated with 
lumor. (From Makowka L, Nalesnik MA, Stieber A, et al: Control of post-transplant Iympho-
proliferative disorders and Kaposi's sarcoma by modulation of immunosuppression, in 
Good RA, Lindenlaub E (eds): Symposia Medica Hoechst. The Nature, Cellular, and Bio-
chemical Basis and Management of Immunodeficiencies. Stuttgart-New York, FK Schat-
tauer Verlag , 1987, pp 567-624. Reproduced with permission.) 
fore, while the biology of this disorder is being debated, there can 
be no question as to the clinical approach to the treatment of KS in 
transplant recipients: reduction of immunosuppression and man-
agement of local complications. This case is presented to demon-
strate the similarity in therapeutic approach between these PNO dis-
parate tumors, PTLD and Kaposi's sarcoma, which arise under 
similar circumstances. 
CONCLUDING COMMENTS 
At the outset of this monograph it was stated that the immune 
system plays a key role at every step in the pathogenesis of PTLD. 
By analogy, the surgeon plays a key role at every step in the cure of 
this disease. These steps include (1) the maintenance of allograft tol-
erance using the minimum amount of immunosuppressive medica-
tion; (2) maintaining a high level of suspicion for PTLD in the setting 
of viral syndrome with lymphadenopathy, organ dysfunction etc.; (3) 
prompt biopsy of appropriate tissue specimens for diagnostic pur-
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FIG 21. 
Follow-up GI series after complete discontinuation of immunosuppression and resolution 
of GI symptoms demonstrates normal mucosal pattern and no evidence of KS . (From 
Makowka L, Nalesnik MA, Stieber A, et al : Control of post-transplant Iymphoproliferative 
disorders and Kaposi 's sarcoma by modulation of immunosuppression, in Good RA, Lin-
denlaub E (eds): Symposia Medica Hoechst. The Nature, Cellular, and Biochemical Basis 
and Management 01 Immunodeficiencies . Stuttgart- New York, FK Schattauer Verlag, 
1987, pp 567-624. Reproduced with permission.) 
poses; (4) close collaboration with the pathologist to ensure the ap-
propriate handling of tissue for clonal analysis, karyotype, and viral 
analysis at a minimum; (5) willingness to challenge a pathologic di-
agnosis of generic non-Hodgkin's lymphoma in a transplant recipi-
ent; (6) provision of emergency surgical intervention for complica-
tions of large or strategically placed PTLDs; (7) judicious reduction 
of immunosuppression as a primary intervention for the control of 
PTLD. 
The recognition that most cases of PTLDs represent treatable tu-
mors removed the specter of hoplessness previously attached to the 
diagnosis of lymphoma in the transplant patient population. Simi-
larly, a realization that the powerful immunosuppressant Cyclospor-
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ine A did not result in a large increase in the number of such tumors 
allowed numerous allograft recipients to enjoy the benefits of this 
drug, and allows the further development of immunosuppressive 
agents that act by similar mechanisms. 
Presently, several centers are analyzing these tumors for hints that 
relate to the general questions of tumor progression and host im-
mune control of tumors. Others are investigating the application of 
a vaccine against the Epstein-Barr virus. Early enthusiasm for the 
usefulness of such a vaccine in control of lymphoid tumors has re-
cently been downplayed. However, perfection of such a vaccine 
would undoubtedly play an important role in removing the major 
known etiologic factor of these lesions and thus preventing tumor 
development. The human and financial savings offered by such an 
ability would be substantial. Likewise, dissection of the mechanism 
by which the immune system is able to cause regression of Prill 
may give insight into forms of immune augmentation therapy suit-
able for some cases of AIDS lymphomas. 
The dream of the transplant surgeon is to achieve a specific allo-
graft tolerance in the recipient without compromise of any other 
function of the immune system. This goal will no doubt be realized. 
When it is, Prills and similarly arising tumors will no longer be 
seen. 
Meanwhile, we should seize the opportunity provided by this ex-
periment of nature-and man-to understand how a serious but 
uncommon side effect of organ transplantation actually reflects a 
perturbation of delicately balanced systems that have evolved over 
the millennia. 
APPENDIX: TECHNICAL CONSIDERATIONS RELATED TO THE 
STUDY OF POSTTRANSPLANT LYMPHOPROLIFERATIVE 
DISORDERS 
REVIEW OF IMMUNE INTERACTIONS AND RELEVANT METHODS 
OF ANALYSIS 
Cellular Interactions 
Manipulation of the immune response produces a tolerant state 
that allows survival of a foreign graft. It also provides the backdrop, 
in the appropriate setting, for the development of PTLD. Reconsti-
tution of the immune response is a contributor to the rejection of 
PTLD, but this may also precipitate allograft rejection. A comprehen-
sive review of transplantation immunology and tumor immunology 
is beyond the scope of this monograph, but it is appropriate to re-
view some fundamental aspects of the immune response in order to 
provide a context from which to discuss the pathogenesis and be-
havior of PrLDs. 
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The major cellular components of the immune system are the 
lymphocytes and macrophages. Lymphocytes are most simply sub-
divided into two general classes: B-Iymphocytes, which are respon-
sible for antibody production, and T-Iymphocytes, which include ef-
fector cells and regulatory (helper and suppressor) cells. (Other cells, 
such as NK cells, which also play important roles in the immune 
response, and considered below). Following an antigenic challenge 
to the host, the normal immune response can also be divided into 
two interconnected stages, namely the induction (afferent) phase 
and the effector (efferent) phase (Fig 22). During the induction phase, 
a carefully orchestrated interaction occurs first between host im-
mune cells and the inciting agent (antigen) and later among the var-
ious host immune cells. The outcome of this cellular conversation is 
the selection, activation and proliferation of that subset of cells 
which, under ideal circumstances, is best suited to deal with the 
antigenic challenge. The effector phase represents the vector sum of 
all actions taken by the recruited cells to eliminate the antigen. 
Some, but not all, of these effector mechanisms are also illustrated 
in Figure 22. 
In parallel with the induction and effector phases, a specific reg-
ulatory network evolves in order to terminate the immune response 
at the appropriate time. Simultaneously, selected immune cells are 
diverted from the main pool to contribute to the cumulative and 
long-lived immunologic memory system of the host. 
The actions of T-Iymphocytes and B-Iymphocytes are best consid-
ered separately, although they invariably act in concert during the 
integrated immune response. T-cells respond to antigen that has 
been processed by an antigen-presenting cell, usually of macro-
phage origin. The antigen is recognized only in association with cer-
tain molecules (major histocompatibility or MHC antigens) present 
on the surface of the antigen-presenting cell. The presence of spe-
cific MHC antigens provides a means by which the immune system 
can distinguish "self' from "non-self' cells. "Non-self' cells have ei-
ther different MHC antigens, in which case they will be recognized 
as foreign, or no MHC antigens, in which case they will not be rec-
ognized by this mechanism. This duall'ecognition forms the basis of 
"MHC-restriction" of many T-cell mediated immune responses.27:1 
A variety of T -cells with different functions may respond to the 
antigen-MHC complex.208 Cytotoxic T -lymphocytes mediate direct 
killing of cells or organisms containing the inciting antigen. The ac-
tions of cytotoxic T-cells are up-regulated by factors elaborated from 
T-helper lymphocytes and down-regulated by factors secreted from 
T-suppressor cells. A separate set of T-cells is involved in secreting 
factors that activate macrophages as part of the delayed type hyper-
sensitivity response. These T -cells are also under the control of 
helper and suppressor T-subsets. In addition, T-helper and T-sup-
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FIG 22. 
Schematic representation of afferent (within box) and efferent (outside box) cellular im-
mune interactions. Antigen combines with antigen-presenting cell (APe), usually a mac-
rophage and interacts with a specific resting T cell (not shown). With the help of IL-2 the 
T cell is activated into a helper cell (Th) which secretes a variety of Iymphokines. notably 
IL-2. This Iymphokine in conjunction with IL-1 activates other T cells, including suppressor 
(Ts), cytotoxic (Tc) and delayed hypersensitivity (Tdh) T lymphocytes. T helper cells exert 
a positive influence, and T suppressor cells a negative influence, on subsequent devel-
opment of the T cell system into mature effector cells. Meanwhile, B cells also interact with 
antigen either in conjunction with (Bdep) or independent from (Bind) direct Interaction with 
T cells. A variety of interleukins are required to drive subsequent B cell proliferation and 
differentiation into antibody-producing plasma cells (PC). In the efferent arm of the im-
mune response, a variety of products deal with antigen-bearing structures (oval). Cyto-
toxic T cells may directly attach to and inflict damage upon the target. Delayed hypersen-
sitivity cells marshal a number of factors to deal with the target. Some results are directly 
mediated by macrophages (M). Natural killer cells (NK) also inflict damage directly similar 
to cytotoxic T cells. Antibodies attach directly to the target and may aggregate it for sub-
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pressor cells influence the growth of certain responding B-Iympho-
cytes in opposing fashions. 
A schema depicting the central role of the helper T -lymphocyte in 
the cascade of reactions necessary for an effective immune response 
is shown in Figure 22. In this example, a macrophage with specific 
surface receptors recognizes a foreign antigen and acts as the anti-
gen presenting cell. A T-helper lymphocyte with receptors to the 
same antigen recognizes this antigen on the surface of the macro-
phage in association with self-MHC antigens. This recognition event 
triggers a number of intracellular responses within the T-cell, result-
ing in its activation.208 The activated T-cell produces a number of 
functional molecules, some of which remain on its cell membrane 
as receptors, and others which are secreted into the extracellular 
space to act on nearby cells. The secreted substances are called lym-
phokines. 
Lymphokines, which were originally thought only to affect cells of 
the immune system, are now known to have effects as diverse as 
hepatocyte stimulation and sleep induction. For these reasons they 
are also referred to as cytokines. Nevertheless, their major role is to 
fmro an amplification mechanism bridging the induction and effec-
tor phases of the immune response.73 
Interleukin-l is produced by monocytes and is more properly con-
sidered a monokine. This molecule acts as a cofactor in the activa-
tion of T-cells, facilitates the production of other lymphocytes and 
also acts as a cofactor in B-cell activation. The activated T-cell pro-
duces interleukins 2, 3 and 4, gamma interferon and B-cell differen-
tiating factor.73 Since the activated T-cell also expresses surface re-
ceptors for interleukin-2, a positive feedback loop is established. 
Interleukin-2 causes clonal expansion of the activated T cells, an ef-
fect that also requires the continued presence of antigen. 
A positive feedback loop is also established by the production of 
gamma interferon. This lymphokine, among its many other effects, 
increases MHC expression on antigen presenting cells. This facili-
tates antigen presentation and thus activation of T-cells.73 
B-cell responses to antigen can be categorized as either T-depen-
dent or T-independent. A T-dependent response is defined as one 
that requires two steps for B-cell activation: (1) recognition of a for-
eign antigen by a B-Iymphocyte with specific receptors, and (2) rec-
ognition of the antigen-MHC complex on the surface of the B cell by 
a helper T-Iymphocyte. In contrast, a T-independent response re-
quires only the initial interaction between B-Iymphocyte and antigen 
sequent removal. Altematively they may serve as a bridge for activated complement, re-
sulting in "holes" in the target. Antibody may also serve as a bridge for the attachment of 
killer lymphocytes (K). This is referred to as antibody-dependent cellular cytotoxicity 
(ADCC). Not shown are immune dampening mechanisms and memory cell generation. 
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to occur in order to trigger B-ceU activation. In either case, further 
proliferation and differentiation of the activated B cell is dependent 
upon the presence of lymphokines.126,139 The activated B-Iympho-
cyte is acted upon by interleukin-4 (B-cell stimulating factor 1) and 
B-cell differentiating factor (B-cell stimulating factor-2). These lym-
phokines may act by stimulating a variety of B-cell surface receptors 
in a sequential pattern.44, 139 Other lymphokines seIVe to enhance or 
diminish the effects of these molecules. The end result is B-cell pro-
liferation and differentiation into antibody-producing plasma cells. 
Thus, in a strict sense, all B-cell responses have dependence on T-
lymphocytes. This pathway is outlined in Figure 22 and a represen-
tation of the antibody molecule is shown in Figure 23. 
Despite the exquisite interdependence of the various components 
of the immune system, the redundancy of these interconnections 
must be stressed. If one pathway of response is blocked, several oth-
ers are available to take its place. This redundancy is also manifest 
as a mUltiplicity of mechanisms available to perfom1 a single func-
tion. The effector function of immune cytotoxicity is a case in point. 
A cell bearing an antigenic stimulus may be lysed by one of several 
mechanisms (see Fig 22). An antibody molecule attached to the cell 
surface may activate the complement system, leading to the forma-
tion of a membrane attack complex. This complex forms small tu-
bules that span the full thickness of the cell membrane leading to 
cell lysis. Alternatively, the antibody molecule may seIVe as a bridge 
to connect the target cell to an effector lymphocyte known as a K 
(killer) cell. The reaction mediated by this cell is known as antibody-
dependent cellular cytotoxicity (ADCC). NK cells (natural killer cells), 
which may be important in tumor resistance, effect target cell lysis 
by mechanisms similar to that used by the complement system. 
These cells attach directly via specific NK determinants on the cells. 
The relationship of K cells and NK cells to other lymphocytes is 
unresolved at present. Indeed, it is not known whether these activi-
ties are mediated by the same cell type. Therefore it is best to con-
sider "K cell" and "NK cell" as functional definitions of the cells 
mediating ADCC and NK activities, respectively. 
The cytotoxic T-Iymphocyte represents yet another entity capable 
of lysing a target cell. As is the general case for T-cell recognition of 
antigen, the cytotoxic reaction in this case is limited by MHC-restric-
tion. Macrophages may also act as immune effector cells by virtue of 
their phagocytic and enzymatic properties. 
The interrelationship of B-cells and T-cells also forms an impor-
tant link in the pathogenesis of PTLD, especially in terms of control 
mechanisms. In this regard, E. Klein has emphasized that B-cell pro-
liferation is normally under tight T-cell control. She suggests that 
these normal physiologic immune control mechanisms may also be 
operative in control of rampant EBV-associated B cell lymphoproli-
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Schematic representation of antibody molecule. This IgG molecule is composed of two 
heavy chains and two light chains. On the left side of the picture, heavy and light chains 
are contained withiin separate boxes. On the right side, they are broken down into defined 
globular regions called domains. The light chain, in this case a kappa chain, is composed 
of one variable (Vk) and one constant (Ck) domain. The heavy chain, which in the case of 
IgG is called a gamma chain, is composed of one variable (VH) and three constant (CH1, 
CH2, CH3) chains. There is some degree of mobility at the hinge region, where the chains 
are held together by disulfide bonds (not shown). Antigens are bound by the variable 
regions of heavy and light chains, as illustrated. fn contrast, most of the tags used to 
visualize antibodies in various immunocytochemical techniques (e.g., fluorescent, enzyme, 
or radioactive tags) bind to the heavy chains at sites removed from the antigen attach-
ment. These areas are normally responsible for other activities, e.g., complement binding. 
feration. 141 Homeostatic T-B control mechanisms have also been sug-
gested to playa role in the down-regulation of B-cell proliferation in 
uncomplicated infectious mononucleosis.140 However, as shown in 
the previous discussion, current models of PTLD stress the cytotoxic 
T-cell response as the predominant host control mechanism in this 
disorder. 
Methodologies Employed in the Identification of Lymphocytes 
The cooperative interactions between T- and B-lymphocytes were 
totally unknown prior to the 1960s. This was due to an inability to 
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distinguish these cell types, which have similar appearances at a 
microsopic and ultrastructural level. 
Clearly, a method for separating these cells was needed. The so-
lution was to be found in the presence of specific molecules, located 
on or within the cells, that could be utilized as specific markers for 
individual cell subpopulations. The methods that were developed 
also provided a means by which the clonal composition of lympho-
proliferative disorders, including PTLDs, could be evaluated. 
The technique used to locate such molecules had originally been 
devised by Coons in 1942 to identify Pneumococcus within tissue 
sections.52a Known as the fluorescent antibody technique, it ex-
ploited the exquisite sensitivity of the antigen-antibody reaction to 
locate specific molecules of interest. In theory, the concept was sim-
ple: if an antibody could be raised against a particular antigen, then 
it would react with that antigen. Further, if the antibody could itself 
be made visible, then the reaction would by inference show all lo-
cations of the specific antigen. It was discovered that antibodies 
could be combined with such visualizing reagents and still maintain 
the ability to combine specifically with antigens. This was so be-
cause the antibody-antigen combining site and the site amenable to 
combination with visualizing reagents were located on two separate 
portions of the antibody molecule (see Fig 23). A fluorescent com-
pound derived from the interaction of 4-amino fluorescein and the 
World War I poison gas phosgene served as the marker in the first 
set of studies and prompted the descriptive term fluorescent anti-
body. Since that time, a variety of compounds and modifications 
have been used to identify antigens, all based on the same principle. 
The names of the specific techniques derive from the identity of the 
visualizing reagent conjugated to the antibody molecule. For exam-
ple, immunoperoxidase techniques utilize the enzyme horseradish 
peroxidase to localize the antigen-antibody reaction, immunogold 
techniques utilize conjugated gold particles, and so on. The terms 
immunocytochemical or immunohistochemical are interchangeably 
applied to refer to this family of techniques. The methods are most 
frequently used to identify antigens in tissue sections (immunohis-
tochemistry) or in cell suspensions (immunocytochemistry). Auto-
mated tabulation of cells stained with one or more fluorescent anti-
bodies is one basic unit of measurement in flow cytometric 
techniques. 
The efficacy of the marker is of little use in the absence of the 
appropriate antibody. The discovery of antibodies specific for B- or 
T -lymphocytes required a number of years and the advent of mon-
oclonal antibodies to reach fruition. 
Early studies of lymphocytes took advantage of the fact that B-cells 
were the source of antibodies. Thus, by raising antibodies against 
antibodies one would be able to identify these cells eo ipso. How-
444 Curr Probl Surg, June 1988 
ever, the only practical means of producing specific antibodies was 
by immunization of animals, collection of serum, and isolation of the 
gamma globulin (antibody-containing) fraction. A single antigen pro-
vokes a multitude of different B-cells to produce an entire popula-
tion of antibodies that are unique but share in common some degree 
of reactivity to the antigen. Such a collection of antibodies is referred 
to as polyclonal to reflect this diverse B-cell origin. The investigator 
is also restricted because the immune system will preferentially re-
spond to highly antigenic structures. Thus molecules that are pres-
ent in minute quantities will evoke little or no detectable response 
in this model. 
In 1975, Kohler and Milstein devised a means whereby the unique 
antibodies produced by clones derived from individual B-cells could 
be isolated in large quantities.149a This discovery of monoclonal an-
tibodies revolutionized the field of immunology and led in 1984 to 
the Nobel prize for these investigators.z63a 
The original technique was based on the idea of fusing the highly 
developed antibody production machinery of the plasma cell (ma-
ture B-cell) together with the genetic blueprints for the assembly of 
an antibody of desired specificity. Since the DNA instructions reside 
in the nucleus and antibody production occurs in the cytoplasm, a 
functional product from such a fusion was at least theoretically pos-
sible. Malignant plasma cells (plasmacytoma cells) were chosen to 
contribute the cytoplasmic component and splenic B-cells were 
chosen to donate the nuclear component. Cells were fused by ex-
posure to Sendai virus and manipulated in a fashion to select the 
hybrid population. Individual cells were then separated and grown 
in vitro. The supernatants of the monoclonal populations were as-
sayed for (monoclonal) antibody activity, and appropriate clones 
were propagated in vitro or in vivo. 
Armed with monoclonal antibodies and immunocytochemical 
techniques, investigators were at last able to identifY specific mole-
cules that were limited in cellular distribution. A series of T-cell dif-
ferentiation antigens were identified in 1980, leading to an explosive 
and decentralized number of discoveries of so-called maturation an-
tigens on T-cells, H-cells, and other cell types. 
A short period of increasing confusion resulted due to the ple-
thora of monoclonal antibodies, each with idiosyncratic names, that 
were raised against lymphocytes. This situation was addressed and 
corrected by two international workshops held in Paris (1982) and 
Boston (1984) and devoted to nomenclature and standardization of 
such reagents.Z07 The result was the identification of differentiation 
clusters (CDs) that were used to designate antigens present on B-
cells, T-cells, or both, at various times within the cell's lifetime.1I2Z07 
Lymphocyte subpopulations will be referred to in this monograph 
by CD number. 
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Methodologies Employed for the Determination of Clonality 
Immunocytochemical Techniques.-During maturation, a B-Iym-
phocyte produces immunoglobulins. A single B-cell (and all of its 
progeny) will produce antibody molecules constructed of one set of 
light chains (kappa or lambda) and one set of heary chains (IgM, A, 
D, G, or E) (see Fig 23). As the cell matures, the expression of heary 
chain may change from one type to another, but the light chain re-
mains invariant. In other words, a kappa-producing B-cell will never 
produce lambda light chains, and vice versa. 
Since a cell produces either kappa or lambda light chain only, this 
provides a means by which one can estimate the clonal status of a 
B-cell proliferation. Normally, the ratio of kappa-bearing B-cells to 
lambda-bearing B-cells is 2: 1.112 Thus, a benign, reactive polyclonal 
proliferation of B-Iymphocytes would contain cells in this approxi-
mate ratio. Conversely, a monoclonal proliferation of B-cells is de-
rived from a single cell. Therefore one would expect the overwhelm-
ing majority of cells in this case to express the same, i.e., either 
kappa or lambda, light chain. 
The total expression of antibody molecules and other cell markers 
that can be detected in a particular tumor by these methods is re-
ferred to as the immunophenotype of the tumor. Utilizing a combi-
nation of histopathology, immunophenotypic analysis, and clinical 
information, at least 17 different types of non-Hodgkin's lymphoma 
can now be recognized.11z Despite the contribution of immunophen-
otypic analysis to the classification of lymphomas, some limitations 
remain. 
During most of its life, the B-cell expresses immunoglobulin on its 
surface. It is not until the latter stages of maturation, especially as 
the cell becomes a plasma cell, that significant amounts of immu-
noglobulin accumulate in the cytoplasm.1l2 Unfortunately, routine 
histologic processing (Le., formalin fixation and paraffin embedding) 
masks the surface immunoglobulins and typically demonstrates only 
cytoplasmic immunoglobulins. (For this reason it is essential that 
the surgeon provides the pathologist with fresh tissue when lym-
phoid tissue is submitted for diagnostic evaluation. Frozen sections 
may be prepared from this tissue for demonstration of surface, as 
well as cytoplasmic, markers. In addition, cell suspensions may be 
prepared for immunophenotypic analysis and the results quantified 
directly). 
A separate set of problems exists in the use of immunoglobulin 
stains to interpret clonality due to the biology of the B-Iymphocyte 
itself. Very primitive B-Iymphocytes do not yet express immunoglob-
ulins, thus preventing clonal analYSis of primitive B-cell tumors by 
this technique. Such tumors have been referred to in the past as 
"null-cell lymphomas. ,,49 Immunocytochemical methodology also is 
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not very good at detecting the presence of a monoclonal prolifera-
tion in a polyclonal background. If the normal polyclonal 
kappa: lambda ratio is 2: 1, at what point does one assign a cutoff 
that will define a proliferation as monoclonal? The literature is not 
clear on this subject.158, 181, 242 However, it became apparent that a 
more sensitive indicator for diagnostically distinguishing polyclonal 
from monoclonal lymphoid proliferations was desirable. 
Recombinant DNA Techniques.-Simultaneously with the devel-
opment of these phenotypic measures of B- and T-Iymphocyte iden-
tity and maturation, a different group of investigators was making 
seminal discoveries in regard to the genetic maturation of lympho-
cytes. 
Ever since the discovery of the molecular structure of DNA in 1953, 
investigations into the nature of the nucleic acids had been limited 
by the massive size and heterogeneity of these compounds. In this 
regard, the situation was analogous to the restrictions imposed on 
immunologists by polyclonal antibodies, and it required a pivotal 
insight into a means whereby DNA could be made available in a 
more defined form to investigators. 
In 1970, Smith at Johns Hopkins discovered a bacterial enzyme 
that would cleave DNA at a specific site.238a This enzyme, referred to 
as a restriction endonuclease, was the immediate forerunner of a 
large family of enzymes capable of cutting DNA at unique sites. To 
date, over 100 restriction endonucleases have been identified, giving 
the molecular biologist an incredible ability to dissect out reproduc-
ible fragments of DNA. An additional advantage of most restriction 
endonucleases lies in the fact that the scission of DNA takes place 
in an asymmetric fashion, implying that the ends may recombine, or 
reanneal, in a specific fashion. This behavior may be exploited to 
produce large quantities of specific DNA. 
In many cases, bacterial plasm ids are used as the cloning vectors 
for the large-scale production of this specific DNA. Plasmids are 
small circular DNA molecules capable of replication within the host 
bacterium. Defining them as vectors refers to the fact that they will 
be used to carry the desired piece of foreign DNA. Typically, the 
plasmid DNA and DNA of interest are separately cleaved with iden-
tical restriction endonucleases. Products from the two reactions are 
mixed together in the presence of an enzyme known as DNA ligase, 
which facilitates rejoining. Because of the complementary nature of 
the DNA ends, a certain number of reannealings will result in a per-
manent insertion of foreign DNA into vector (plasmid) DNA. The 
plasmids are allowed to enter bacteria that are then cultured. 
Other small DNA particles such as bacteriophages can also be 
used as vectors. Cloning a large number of recombinant DNA parti-
cles results in the construction of a "gene library." The gene library 
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contains numerous unique but random pieces of DNA of interest. In 
order to isolate DNA of a certain specificity from the library, a spe-
cific probe is required. Such probes are constructed by working 
backwards from the protein of interest. The resulting DNA is known 
as complementary DNA (cDNA) since its sequences are complemen-
tary to the mRNA coding for the protein. By radioactively tagging the 
cDNA, one can detect which native DNA fragments contain the gene 
of interest. 
Using such techniques, probes specific for the immunoglobulin 
genes and T-cell receptor genes were discovered during the early 
1980s.66, 119, 120, 261 One of the first clinically useful applications of this 
new technology was the ability to determine the clonal status of B-
and T-Iymphocyte proliferations in cases that previously had been 
indeterminate, such as null cell lymphomas and PTLDs.6,46, 49, 50, 264 
Even before this, an appreciation of the fine structure of immuno-
globulin gene rearrangement of B-cells led to both basic and clini-
cally useful insights. 
Normal Immunoglobulin Gene Rearrangement.-In order to un-
derstand how recombinant DNA analysis is useful in determining 
the clonal composition of B-cell proliferations it is necessary to have 
a working knowledge of the normal genetic changes that occur in 
these cells. 
Each B-Iymphocyte produces an antibody of a single specificity. 
In aggregate, the antibodies produced by an individual host consti-
tute a repertoire of amazing diversity in regard to the ability to re-
spond to different antigens. Indeed, antibodies exist for which the 
antigens have not yet been invented! 
The basis of this antibody heterogeneity exists in the ability of the 
DNA to transpose, or rearrange, itself within each individual B_cell.1so 
The pattern of these rearrangements defines a unique nucleic acid 
sequence, and ultimately a unique amino acid sequence, that deter-
mines the antibody specificity of that B-cell and all its progeny. Rear-
rangements occur within those sections of DNA that code for the 
light chains and the heavy chains that compose the immunoglobu-
lins. The light chain may be one of two types: kappa chain, coded 
for by chromosome 2, or lambda chain, on chromosome 22. All 
heavy chains (G, M, A, D, E) are coded for by a long sequence of DNA 
located on chromosome 14. Since each chain is coded for by several 
discontinuous pieces of DNA on the particular chromosome, the 
rearrangements are necessary to bring these pieces of DNA into ap-
position to form the complete gene. This process is subject to a cer-
tain degree of "looseness" at several levels, which constitutes an in-
genious exploitation by nature to generate unique sequences. This 
looseness was predicted by Burnet almost 30 years ago in the same 
context (see Introduction: Section 3). 
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We will examine rearrangement of the kappa gene, which is the 
simplest case150 (Fig 24). The complete kappa light chain is coded for 
by three separate regions of DNA. These are referred to as the vari-
able region (Vk), the joining region (Jk), and the constant region (Ck). 
First, one of the multiple Vk regions rearranges so as to lie next to 
one of the several Jk regions. The intervening DNA "loops out" and 
is deleted. A Vk gene now lies next to a Jk gene. This complex is still 
separated from the single Ck region by an intervening sequence of 
DNA. The entire length of DNA is translated onto RNA, and the in-
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FIG 24. 
Schematic representation of kappa light chain gene rearangement. In A, the germline 
configuration is shown. At this point, the cell has not rearranged the kappa gene. This 
configuration is retained throughout life in cells other than B lymphocytes. A number of 
variable light chain genes (Vk1-Vkn) are separated by a number of DNA base pairs. Each 
variable gene is preceded by a leader (L) sequence. There are several genes coding for 
the joining region (J1-5). This region joins the variable and constant regions on the im-
munoglobulin light chain. The Joining region genes are separated from the single constant 
chain gene (Ck) by an intervening sequence of DNA (/VS). The crossbars above the DNA 
represent hypothetical recognition sites of a prototypical restriction endonuclease. With 
digestion by the endonuclease, this DNA would fragment into separate portions A-L of 
specific sizes, represented by the distance between crossbars. In B, a rearrangement has 
occurred between one of the variable chain genes (Vk2) and one of the joining region 
genes (J3). All of the DNA between these segments has been lost. Therefore, fragments 
f, g, h, and i, which would be seen if the germline DNA in A were to be digested, are 
no longer generated. In their place, a single fragment (designated f-i) is seen. The other 
restriction fragments would remain the same, since no rearrangements have occurred in 
these areas. Thus fragments a, b, c, d, e, }, k and I would show up as germline bands, 
and the new fragment f-i would show up as a rearranged band on Southem blot. Visual-
ization of fragment f-i requires that a sufficient (monoclonal) number of cells are present 
with this identical rearrangement. C, the messenger RNA derived from this rearranged 
DNA. Unnecessary base pairs have been eliminated by RNA splicing, leaving only those 
genes necessary to directly code for the kappa light chain. 
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tervening sequence is spliced out, leaving a messenger RNA with 
only the necessary ingredients for coding the kappa light chain. 
In the case of the lambda light chain (not shown), similar rear-
rangements occur, although these are somewhat more complex due 
to inherited variability in this gene. In the case of the heavy chain 
rearrangements, an additional gene (Dh) codes for the "diversity" re-
gion. This gene also rearranges at an early stage in the life of the cell, 
further expanding the range of possible antibody speCificities.! 
It will be recalled that the normal cell is diploid, that is, it contains 
two sets, or alleles, of every gene. The immunoglobulin genes are no 
exception. Because the rearrangement process is so complex, mis-
takes are frequent. These mistakes generally result in a nonfunc-
tional gene. Somehow this signals the cell to "try again" on the other 
allele. In other words, the cell gets 2 chances to make a productive 
kappa light chain gene. If these both fail, it then gets two chances to 
try with the lambda light chain gene. All of the heavy chain gene 
fragments are linked, so there are also two chances to construct a 
productive heavy chain gene. A definite hierarchy of rearrangements 
also exists in normal cells?50 Thus, heavy chain rearrangement oc-
curs first. If the cell fails at this, it cannot become a functional B cell 
and is probably aborted. Following heavy chain rearrangement, the 
cell attempts to make light chains: first with the kappa genes and, if 
this is unsuccessful, then with the lambda genes. The result of suc-
cessful gene rearrangement is the production of a complete and 
unique antibody molecule that will be produced by that B cell and 
all of its progeny. The diagnostic exploitation of this phenomenon 
for purposes of clonal determination of B-cell proliferations will be 
considered next. 
Use of Recombinant DNA Techniques to Assess Clonal Composi-
tion.-DNA can be cut into specific fragments by the use of restric-
tion endonuclease enzymes, described above. When genetic rear-
rangements (e.g., immunogloblin gene rearrangements) occur, 
however, the positions of some of the endonuclease recognition sites 
are moved (see Fig 24). Thus the sizes of digested fragments flanked 
by these rearranged sites will be different from that of germline DNA. 
Detecting differences in the sizes of digested DNA fragments al-
lows us to separate those DNAs that have undergone rearrange-
ments from those that have not. DNA can be separated by the use 
of gel electrophoresis. In this technique, the digested sample is 
placed in a gel that is cast from agarose or polyacrylamide, and an 
electrical current is applied to the gel (Fig 25). Conditions can be 
manipulated so that the specimen migrates according to molecular 
weight, net charge, or some combination of the two. For our pur-
poses it is desirable to separate the digested DNA fragments by mo-
lecular weight, i.e., size., alone. 
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Simplified flow diagram of Southern blotting for determination of immunoglobulin gene 
rearrangements. A bacterial host (x) serves for the reproduction of plasm ids (small circles) 
which contain a DNA probe for a portion of the immunoglobulin gene. The procedures 
used to insert the DNA probe into the plasmid are not shown here. The plasmids are 
isolated from the bacteria (1) and the DNA of interest (dark color) is separated using 
restriction endonucleases. This DNA is tagged with radioactive material to serve as a 
probe. Meanwhile, the human lymphocytes (z) are disrupted, and the human DNA is iso-
lated (3). This is cut into a number of irregularly sized pieces by restriction endonucleases 
(4). The DNA will be separated according to size using a gel into which small wells have 
been cut to hold the DNA for electrophoresis (5). Once applied to the gel (6), the DNA 
migrates under the influence of an electrical field (7). The gel in this diagram is drawn to 
contain four separate specimens, which will migrate under the same conditions. The hy-
pothetical results of the electrophoresis are shown (8). At this point, the bands are not 
visible. They are displayed in (8) and (9) for the sake of clarity. In order to stablize the 
DNA and prevent further diffusion, the gel is blotted onto nitrocellulose paper, which pro-
duces a replicate pattern of the DNA bands (9). This paper is then incubated together 
with the radioactively tagged DNA probe (10), and the final product is placed on X-ray 
film. The resulting autoradiogram (11) will show bands only at the sites where the radio-
active probe DNA has bound to the underlying human DNA and exposed the Xray film. In 
this hypothetical exarnple, the similar patterns of lanes B, C, and D (11) are used to depict 
a germline, or unrearranged, DNA pattern. In contrast, lane A shows a loss of the germline 
bands and displays two new rearranged bands. Lane A contains DNA from a monoclonal 
8-cell lesion, and lanes B-D contain only polyclonal lymphoid cells. 
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Having done this, it is necessary to be able to localize the partic-
ular gene of interest. To do this requires the use of a specific probe, 
composed of DNA that is complementary in sequence to the DNA to 
be examined. Probes may be constructed by a variety of techniques. 
The probe is usually labeled with a radioactive substance such as 
32p. Obviously the probe will bind to the DNA against which it is 
directed, regardless of location on the gel. In this way the size of the 
particular DNA fragment can be deduced when an autoradiogram of 
the separated DNA with bound probe is made. 
During incubation steps it is helpful to immobilize the separated 
DNA so as to eliminate problems related to diffusion in the gel. This 
immobilization is achieved by blotting the gel with nitrocellulose pa-
per. The paper absorbs and covalently bonds the DNA, thus repro-
ducing and preserving the results of the electrophoretic separation. 
This approach to the analysis of DNA is referred to as Southern blot-
ting, first described in 1975.240 Similar techniques, developed for the 
analysis of RNA and protein, have been called Northern blot and 
Western blot, respectively. 
In the particular case of B-Iymphocytes, the probes of interest are 
directed against either the hea"Y chain gene region or the kappa or 
lambda light chain genes. We will consider the hea"Y chain probe as 
a prototype. 
In all cells with non rearranged immunoglobulin hea"Y chain re-
gions, a specific pattern, called germline, will be seen on Southern 
blotting. This pattern is seen in all non-B-cells and in any future B-
cells that have not yet rearranged their immunoglobulin genes. In B-
cells with a rearranged hea"Y chain gene, the rearrangement will 
most likely cause a change in the size of some of the fragments gen-
erated by digestion with restriction endonucleases. It is possible, of 
course, that a rearrangement will result in fragments in which all of 
the endonuclease recognition sites on the DNA happen to have the 
exact same number of nucleotides between them, resulting in a pat-
tern indistinguishable from germline. However, this possibility is 
quite remote. 
In a polyclonal (nonclonal) proliferation of B-cells, each cell will 
have a unique rearrangement. Thus, when subject to electrophore-
sis, each fragment will move to a slightly different location, depend-
ing upon size. However, each fragment will continue to label with 
the specific radioactive probe. The result will be a "blur" on autora-
diogram, in which the pattern produced by any individual cell will 
be below the threshold of detection. 
If, however, a monoclonal population is present in the prolifera-
tion, the DNA of each cell comprising that clone will be cut in ex-
actly the same way, and the size will be different from the germline 
configuration. Therefore a distinct band pattern will emerge by 
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Southern blot, and this will permit the diagnosis of a monoclonal 
proliferation (Fig 26) .6. 46 
A similar approach can be used to diagnose T-cell proliferations 
using a probe for the T-cell receptor. The gene for this receptor is 
related to the immunoglobulin gene, contains V, D, J , and C seg-
ments, and undergoes unique rearrangements in a manner probably 
very similar to that of the immunoglobulin genes.24 , 123 
Only B-Iymphocytes regularly show rearrangements of hea\)' and 
light chain immunoglobulin genes. Occasional T-cell tumors may 
also have rearrangements of the hea\)' chain, and rarely the light 
FIG 26. 
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Representative autoradiogram showing heavy chain immunoglobulin gene rearangement. 
Five separate lanes contain DNA isolated from control liver and tumors designated as I, 
0, 0 and J. Position of DNAs of varying molecular weights in kilobases (kb) is given on 
scale to left. It can be seen that smaller fragments migrate further. Bands in each lane 
represent DNA hybridized to a radioactively labeled probe specific for a region of the 
heavy chain . Liver DNA serves to define the germline (unrearrangedi pattern. A similar 
pattern is seen in lanes I, D and D. In contrast , a rearranged band is seen in lane J. This 
band represents DNA from a monoclonal population of B lymphocytes. (From Nalesnik 
MA, et al: Clonal characteristics of post-transplant Iymphoproliferative disorders. Trans-
plant Proc 1988; 20(suppl 1 ):280-283. Reproduced with permission.) 
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chain, gene in association with rearrangements of the specific T-cell 
receptor. Conversely, occasional B-cell tumors show rearrangement 
of the T-cell receptor J3-chain gene in association with immunoglob-
ulin gene rearrangements.6 , 106, 183, 228, 265 Thus, whereas a heary chain 
rearrangement represents conclusive proof of clonality and strongly 
implicates that B-lymphocyte as the cell of origin, aT-lymphocyte 
origin cannot be ruled out unless follow-up analyses are also per-
formed.183,228 
The immunogenotypic DNA rearrangement studies are more sen-
sitive than the immunophenotypic immunocytochemical tech-
niques, and they are capable of detecting a clonal component when 
it makes up only 5% of the DNA analyzed.6 Other estimates have 
lowered this figure to 1 % .50 Currently, however, the turnaround time 
for this procedure is on the order of several weeks, rendering it less 
than useful in the acute clinical setting. It can be anticipated that 
major progress in accelerating the procedure will be achieved in the 
near future. 
CONSIDERATIONS IN THE DIAGNOSIS OF BENIGN VERSUS 
MALIGNANT LYMPHOID NEOPlASMS 
Introduction 
It is clinically convenient to be able to divide tumors into benign 
and malignant forms. In most cases this is easily accomplished, and 
the contemporary form of appropriate therapy is undertaken by the 
physician. However, the distinction between benign and malignant 
proliferations is made less clear by experimental carcinogenesis re-
search throughout this century, which has led to the conclusion 
that cancer is a multistep process.53, 54, 63, 72, 87--89, 143, 147, 156, 216, 217, 225 
Similar to the replacement of classical physics by quantum mechan-
ics in the first half of the 20th century, the results of this research 
do not overthrow our clinical understanding of cancer, but simply 
expand it. 
It is likely that most cancers, by the time of their clinical appear-
ance, have evolved to a fully malignant state. Other growths (e.g., 
fibroadenoma) are detected during a prolonged benign period that 
may extend for the lifetime of the host. A limited number of tumors 
have behaviors somewhat intermediate between these two catego-
ries and usually are stubbornly recurrent. A fourth category may 
show a rapidly progressive and finely graded progression from be-
nign to malignant. It is into this last category that PI'LD appears to 
fall. For this reason, complete understanding of these tUmors may 
ultimately prove to have importance well beyond its immediate ap-
plicability to this highly restricted group of patients. 
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Tumor Progression 
A terminology for the natural history of cancer was developed on 
the basis of animal experiments and clinical observations conducted 
during the early and middle parts of this century. This terminology 
is independent of the particular type of cancer and is used to codifY 
various stages of pre neoplasia and neoplasia at a cellular level. 
On the basis of studies of skin cancer resulting from the applica-
tion of tars to rabbit skin, Rous and colleagues87. 89. 217 distinguished 
two antecedents of neoplasia, namely cellular "initiation" and "pro-
motion." A stimulus capable of initiation caused an irreversible cel-
lular response that resulted in the production of latent tumor cells. 
A tumor promoter caused hyperplasia of the affected cells, probably 
along with a delay in maturation. In contrast to initiation, promotion 
was a reversible event and could subside following withdrawal of the 
stimulus. 
Further growth of the tumor was dependent on a process called 
tumor "progression." This concept was initiated by the work of 
ROUS,216 promoted by the principles of Foulds,87. 88 and promulgated 
and extended by the Kleins.142-144 It proposes that the structure and 
behavior of tumors are composed of particular unit characters. 
These units may progress independently in a continuous or discon-
tinuous manner along alternate paths of development. The units 
control rate of growth, differentiation, metastatic potential, and other 
characteristics. This model predicts that multiple tumors in the 
same host may progress independently of each other. It also asserts 
that a neoplasm most likely will not fully evolve during the lifetime 
of the host. In other words, given enough time, it will become even 
more malignant. 
This concept also has implications for the beginning stages of tu-
mor development. In the words of Foulds, "Malignancy is essentially 
a clinical concept . . . A tumor may have one or more of the recog-
nized criteria of malignancy; it may have all of them and kill the 
patient and yet be responsive and 'conditional' ."87 The term condi-
tional was first used by ROUS217 to refer to neoplastic growths that 
were dependent upon outside aid (i.e., tar administration in his an-
imal model) for continued survival. 
In discussing PTLD we will develop the case that many of these 
tumors represent conditional neoplasias. We define conditional neo-
plasia in the current context as a neoplastic proliferation of cells that 
is normally forbidden by the immunocompetent host. In the immu-
nodeficient individual, however, the "outside aid" is supplied by the 
removal of host control mechanisms. The tumors may therefore act 
as clinically aggressive malignancies that can rapidly lead to death. 
The pathologic and clinical spectrums of PTLDs also suggest that 
they may undergo tumor progression in the classic sense outlined 
above. 
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Oncogenes 
The concept of oncogenes, or cancer genes, derived from two ini-
tially unrelated fields of study. The first was the analysis of the com-
position of viruses capable of inducing neoplasms in susceptible an-
imals, (acutely transforming retroviruses) and the second area was 
the study of the effect that DNA fragments derived from tumors had 
when inserted into certain cell culture systems (DNA transfection 
studies of NIH 3T3 fibroblasts).l1 
In both cases, cmtain genes were isolated that appeared to confer 
neoplastic potential on eukmyotic cells. In viruses these sequences 
were known as the v-onc genes. They were thought to originate in 
and be derived from the cellular homologs, or c-onc genes.s C-onc 
genes have been significantly conserved throughout evolution and 
are thought to play significant, but poorly characterized, roles in 
normal cell growth and differentiation. The more than 20 known on-
cogenes have been tentatively divided into several families based on 
their known characteristics. Since the oncogene products are nor-
mal cellular constituents, their products would not normally be ex-
pected to induce a host immune response.141 However, some DNA 
viruses produce their own transforming proteins, which may be an-
tigenic to the host. 
Deregulation of the production of oncogene products is thought 
to play' a significant role in the progression of neoplastic potential. 
Several lines of investigation have indicated that the effects of the 
deregulation of 2 or more oncogenes may be complementary and 
additive as regards the malignant phenotype.2o, 63 (However, more re-
cent studies have indicated that the action of a single oncogene may 
be enhanced by mUltiple abnormalities within it, abrogating the ne-
cessity for a second oncogene.)20,63 Thus, to some degree, the onco-
genes provide basic building blocks in constructing the "unit char-
acteristics" of progressive neoplasia first elaborated by Foulds. 
Oncogenes may be inappropriately activated by a number of 
mechanisms.s,2o In the case of the acutely transforming retroviruses, 
active oncogenes are transmitted to many cells by the virus vector, 
causing polyclonal tumors. Cellular oncogenes may be inappro-
priately activated by coming under the influence of a viral promoter, 
or by a genetic recombination in which the normally silent onco-
gene is rearranged to become part of an active gene. Actual dupli-
cations, or amplification of the oncogene, may occur, leading to in-
creased product. Additionally, a mutation in the oncogene may code 
for a protein that provides an aberrant growth signal.ll Finally, one 
must consider the possibility that inactivation of an oncogene sup-
pressor mechanism may be the initial event leading to increased on-
cogene expression.s.143 
The c-myc oncogene has particular relevance to Burkitt's lym-
456 Curr Prabl Surg, June 1988 
phoma.58-60, 64, 143 Products of this gene probably playa role in normal 
cellular proliferation, acting together as a transducer which receives 
signals from growth factors and carries out functions at the level of 
the cell nucleus.22o The gene, which has been conserved for over 400 
million years,220 is normally expressed in a coordinated fashion with 
other oncogenes following lymphocyte stimulation?56 Thus, disor-
dered production of the c-myc product may help to maintain a cell 
in a constant state of proliferation. However, this is not thought to 
be a sufficient cause of malignancy in and of itself.162 Recent studies 
in model animal lymphoid tumors suggest that the comcomitant 
deregulation of c-myc with another oncogene, Blym-l, may provide 
the steps necessary for a malignant monoclonal lymphoproliferation 
to arise.53,M A similar multistep process has also been proposed for 
Burkitt's lymphoma.l44 Recently, the copresence of EBV transforma-
tion and c-myc expression has been found to be sufficient to induce 
tumorigenesis in an experimental system.163 
It is important to reiterate the relationship of oncogenes vis a vis 
the acutely transforming retroviruses and the Epstein-Barr virus. The 
acutely transforming retroviruses can induce neoplasia by the inser-
tion into the host genome of oncogenes carried by the virus. The 
Epstein-Barr virus does not carry oncogenes that induce cancer di-
rectly. In Burkitt's lymphoma, the c-myc oncogene, a normal cellular 
component, is activated by chromosomal translocation. The exact 
cause of this translocation remains unknown. Recent reports have 
also suggested that EBV infection may also favor activation of other 
cellular oncogenes.206,254 The significance of this remains to be de-
fined. 
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